Encompass Health (EHC) 10-Q 31 Oct 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 25, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	HEALTHSOUTH CORP
Entity Central Index Key	785,161
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		98,310,804
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Net operating revenues	$ 995.6	$ 926.8	$ 2,951.7	$ 2,757.3
Less: Provision for doubtful accounts	(12.6)	(14.8)	(42.7)	(46.7)
Net operating revenues less provision for doubtful accounts	983	912	2,909	2,710.6
Operating expenses:
Salaries and benefits	542.1	497.4	1,600	1,469.6
Other operating expenses	137.6	126.3	397.2	367
Occupancy costs	18.6	17.6	54.8	53.5
Supplies	36.5	34.8	110.6	104.2
General and administrative expenses	39.7	30.3	128.6	96.6
Depreciation and amortization	46.2	43.5	137.2	128.8
Professional fees—accounting, tax, and legal	0	0	0	1.9
Total operating expenses	820.7	749.9	2,428.4	2,221.6
Loss on early extinguishment of debt	0.3	2.6	10.7	7.4
Interest expense and amortization of debt discounts and fees	36.8	42.5	118.5	130.5
Other income	(1)	(0.8)	(2.9)	(2.1)
Equity in net income of nonconsolidated affiliates	(2.1)	(2.5)	(6.2)	(7.3)
Income from continuing operations before income tax expense	128.3	120.3	360.5	360.5
Provision for income tax expense	43.1	42.1	111.4	124.2
Income from continuing operations	85.2	78.2	249.1	236.3
Loss from discontinued operations, net of tax	(0.1)	(0.1)	(0.2)	(0.3)
Net income	85.1	78.1	248.9	236
Less: Net income attributable to noncontrolling interests	(19.2)	(16.4)	(53.2)	(53.7)
Net income attributable to HealthSouth	$ 65.9	$ 61.7	$ 195.7	$ 182.3
Weighted average common shares outstanding:
Basic (shares)	97.8	89.1	92.3	89.3
Diluted (shares)	99	99.4	99.1	99.5
Basic earnings per share attributable to HealthSouth common shareholders:
Continuing operations (in dollars per share)	$ 0.67	$ 0.69	$ 2.11	$ 2.03
Discontinued operations (in dollars per share)	0	0	0	0
Net Income (in dollars per share)	0.67	0.69	2.11	2.03
Diluted earnings per share attributable to HealthSouth common shareholders:
Continuing operations (in dollars per share)	0.67	0.64	2.08	1.90
Discontinued operations (in dollars per share)	0	0	0	0
Net income (in dollars per share)	0.67	0.64	2.08	1.90
Cash dividends per common share (in dollars per share)	$ 0.25	$ 0.24	$ 0.73	$ 0.70
Amounts attributable to HealthSouth common shareholders:
Income from continuing operations	$ 66	$ 61.8	$ 195.9	$ 182.6
Loss from discontinued operations, net of tax	(0.1)	(0.1)	(0.2)	(0.3)
Net income attributable to HealthSouth	$ 65.9	$ 61.7	$ 195.7	$ 182.3

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
COMPREHENSIVE INCOME
Net income	$ 85.1	$ 78.1	$ 248.9	$ 236
Net change in unrealized gain (loss) on available-for-sale securities:
Unrealized net holding gain (loss) arising during the period	0.1	(0.2)	0.5	0.4
Other comprehensive income (loss) before income taxes	0.1	(0.2)	0.5	0.4
Provision for income tax (expense) benefit related to other comprehensive income items	(0.1)	0.1	(0.2)	(0.2)
Other comprehensive (loss) income, net of tax	0	(0.1)	0.3	0.2
Comprehensive income	85.1	78	249.2	236.2
Comprehensive income attributable to noncontrolling interests	(19.2)	(16.4)	(53.2)	(53.7)
Comprehensive income attributable to HealthSouth	$ 65.9	$ 61.6	$ 196	$ 182.5

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2017		Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 67.6		$ 40.5	$ 76.4	$ 61.6
Accounts receivable, net of allowance for doubtful accounts of $58.5 in 2017; $53.9 in 2016	441.6		443.8
Other current assets	178.2		170.2
Total current assets	687.4		654.5
Property and equipment, net	1,482.3		1,391.8
Goodwill	1,971.7		1,927.2
Intangible assets, net	405.1		411.3
Deferred income tax assets	91.6		75.8
Other long-term assets	245.3		221.3
Total assets	4,883.4	[1]	4,681.9
Current liabilities:
Current portion of long-term debt	31.1		37.1
Accounts payable	81.8		68.3
Accrued expenses and other current liabilities	398.3		370.2
Total current liabilities	511.2		475.6
Long-term debt, net of current portion	2,591.3		2,979.3
Other long-term liabilities	186.4		160
Total Liabilities	3,288.9		3,614.9
Commitments and contingencies
Redeemable noncontrolling interests	221.3		138.3
Shareholders’ equity:
HealthSouth shareholders’ equity	1,136.4		735.9
Noncontrolling interests	236.8		192.8
Total shareholders’ equity	1,373.2		928.7	$ 913.8	$ 779.3
Total liabilities and shareholders' equity	$ 4,883.4	[1]	$ 4,681.9
[1]	Our consolidated assets as of September 30, 2017 and December 31, 2016 include total assets of variable interest entities of $262.7 million and $262.3 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2017 and December 31, 2016 include total liabilities of the variable interest entities of $53.9 million and $50.3 million, respectively. See Note 3, Variable Interest Entities.

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 58.5	$ 53.9
Total assets of variable interest entities	262.7	262.3
Total liabilities of variable interest entities	$ 53.9	$ 50.3

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Capital in Excess of Par Value	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2015	$ 779.3	$ 1.1	$ 2,834.9	$ (1,696)	$ (1.2)	$ (527.4)	$ 167.9
Balance at beginning of period (shares) at Dec. 31, 2015		90.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	224.8			182.3			42.5
Receipt of treasury stock	(9.9)					(9.9)
Receipt of treasury stock (shares)		(0.4)
Dividends declared on common stock	(63.4)		(63.4)
Stock-based compensation	16.1		16.1
Stock options exercised	1.8		6.6			(4.8)
Stock options exercised (shares)		0.3
Distributions declared	(43.1)						(43.1)
Capital contributions from consolidated affiliates	17						17
Fair value adjustments to redeemable noncontrolling interests, net of tax	10.2		10.2
Repurchases of common stock in open market	(24.1)					(24.1)
Repurchases of common stock in open market (shares)		(0.7)
Other	5.1	$ 0	2.4	0	0.2	(0.7)	3.2
Other (shares)		0.5
Balance at end of period at Sep. 30, 2016	913.8	$ 1.1	2,806.8	(1,513.7)	(1)	(566.9)	187.5
Balance at end of period (shares) at Sep. 30, 2016		89.8
Balance at beginning of period at Dec. 31, 2016	928.7	$ 1.1	2,799.1	(1,448.4)	(1.2)	(614.7)	192.8
Balance at beginning of period (shares) at Dec. 31, 2016		88.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	239			195.7			43.3
Receipt of treasury stock	(19.8)					(19.8)
Receipt of treasury stock (shares)		(0.9)
Dividends declared on common stock	(70.3)		(70.3)
Stock-based compensation	15.2		15.2
Stock options exercised	1.1		20.4			(19.3)
Stock options exercised (shares)		1.1
Stock warrants exercised	26.6		26.6
Stock warrants exercised (shares)		0.7
Distributions declared	(37.1)						(37.1)
Capital contributions from consolidated affiliates	37.8						37.8
Fair value adjustments to redeemable noncontrolling interests, net of tax	(44.4)		(44.4)
Repurchases of common stock in open market	(38.1)					(38.1)
Repurchases of common stock in open market (shares)		(0.9)
Conversion of convertible debt, net of tax			53.7
Conversion of convertible debt, net of tax (shares)		8.9
Stock Issued During Period, Value, Conversion of Convertible Securities	328.2					274.5
Other	6.3		5.7	1.1	0.3	(0.8)	0
Other (shares)		0.5
Balance at end of period at Sep. 30, 2017	$ 1,373.2	$ 1.1	$ 2,806	$ (1,251.6)	$ (0.9)	$ (418.2)	$ 236.8
Balance at end of period (shares) at Sep. 30, 2017		98.3

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net income	$ 248.9	$ 236
Loss from discontinued operations, net of tax	0.2	0.3
Adjustments to reconcile net income to net cash provided by operating activities—
Provision for doubtful accounts	42.7	46.7
Depreciation and amortization	137.2	128.8
Loss on early extinguishment of debt	10.7	7.4
Equity in net income of nonconsolidated affiliates	(6.2)	(7.3)
Distributions from nonconsolidated affiliates	6.6	5.9
Stock-based compensation	37.9	17.4
Deferred tax expense	51.3	110.6
Other, net	9.8	11.7
Change in assets and liabilities, net of acquisitions—
Accounts receivable	(54.2)	(75.7)
Other assets	(7.4)	(4.4)
Accounts payable	6.1	1.9
Accrued payroll	3.1	8.7
Accrued interest payable	7.3	6
Other liabilities	12.5	11.8
Premium paid on redemption of bonds	0	(5.8)
Net cash used in operating activities of discontinued operations	(0.7)	(0.6)
Total adjustments	256.7	263.1
Net cash provided by operating activities	505.8	499.4
Cash flows from investing activities:
Purchases of property and equipment	(155.7)	(113.9)
Additions to capitalized software costs	(14.6)	(17.5)
Acquisitions of businesses, net of cash acquired	(36.6)	(19.6)
Net change in restricted cash	(9.9)	(7.1)
Other, net	7.6	1.8
Net cash used in investing activities	(209.2)	(156.3)
Cash flows from financing activities:
Principal payments on debt, including pre-payments	(125.4)	(195.2)
Borrowings on revolving credit facility	241.3	260
Payments on revolving credit facility	(255.3)	(240)
Repurchases of common stock, including fees and expenses	(38.1)	(24.1)
Dividends paid on common stock	(67)	(62.4)
Proceeds from exercising stock warrants	26.6	0
Distributions paid to noncontrolling interests of consolidated affiliates	(38.3)	(49.5)
Taxes paid on behalf of employees for shares withheld	(19.8)	(9.9)
Other, net	6.5	(7.2)
Net cash used in financing activities	(269.5)	(328.3)
Increase in cash and cash equivalents	27.1	14.8
Cash and cash equivalents at beginning of period	40.5	61.6
Cash and cash equivalents at end of period	67.6	76.4
Supplemental schedule of noncash investing and financing activity
Conversion of convertible debt	$ 319.4	$ 0

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation HealthSouth Corporation, incorporated in Delaware in 1984, including its subsidiaries, is one of the nation’s largest providers of post-acute healthcare services, offering both facility-based and home-based patient services in 36 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. On July 10, 2017, we announced the plan to rebrand and change our name from HealthSouth Corporation to Encompass Health Corporation, effective January 1, 2018. The corporate name change will be accompanied by a NYSE ticker symbol change from “HLS” to “EHC.” On October 20, 2017, our board of directors approved an amended and restated certificate of incorporation in order to change the name effective as of January 1, 2018. Beginning in the first quarter of 2018, both of our business segments will begin transitioning to the Encompass Health name. The accompanying unaudited condensed consolidated financial statements of HealthSouth Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Exhibit 99.1 to HealthSouth’s Current Report on Form 8-K filed with the United States Securities and Exchange Commission on September 18, 2017 (the “ 2016 Form 10-K ”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December 31, 2016 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading. The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented. See also Note 12 , Segment Reporting . Net Operating Revenues — We derived consolidated Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Medicare 75.7 % 74.8 % 75.3 % 75.0 % Medicare Advantage 8.4 % 7.9 % 8.7 % 7.9 % Managed care 9.4 % 10.1 % 9.6 % 9.9 % Medicaid 2.9 % 3.3 % 2.8 % 3.3 % Other third-party payors 1.3 % 1.5 % 1.3 % 1.4 % Workers’ compensation 0.7 % 0.8 % 0.7 % 0.8 % Patients 0.5 % 0.5 % 0.5 % 0.5 % Other income 1.1 % 1.1 % 1.1 % 1.2 % Total 100.0 % 100.0 % 100.0 % 100.0 % Inpatient Rehabilitation Revenues Our inpatient rehabilitation segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Medicare 73.3 % 73.3 % 73.1 % 73.3 % Medicare Advantage 8.1 % 7.6 % 8.4 % 7.7 % Managed care 10.7 % 11.4 % 11.0 % 11.3 % Medicaid 3.4 % 3.0 % 3.1 % 3.0 % Other third-party payors 1.6 % 1.8 % 1.6 % 1.7 % Workers’ compensation 0.9 % 1.0 % 0.9 % 1.0 % Patients 0.6 % 0.6 % 0.6 % 0.6 % Other income 1.4 % 1.3 % 1.3 % 1.4 % Total 100.0 % 100.0 % 100.0 % 100.0 % Home Health and Hospice Revenues Our home health and hospice segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Medicare 85.2 % 81.8 % 84.7 % 82.4 % Medicare Advantage 9.6 % 8.8 % 10.0 % 8.9 % Managed care 3.9 % 4.5 % 3.8 % 3.7 % Medicaid 1.1 % 4.7 % 1.3 % 4.8 % Patients 0.1 % 0.1 % 0.1 % 0.1 % Other income 0.1 % 0.1 % 0.1 % 0.1 % Total 100.0 % 100.0 % 100.0 % 100.0 % See Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2016 Form 10-K for our policies related to Net operating revenues , Accounts receivable , and our Allowance for doubtful accounts. Recent Accounting Pronouncements — In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” and has subsequently issued supplemental and/or clarifying ASUs (collectively “ASC 606”). ASC 606 outlines a five-step framework that intends to clarify the principles for recognizing revenue and eliminate industry-specific guidance. In addition, ASC 606 revises current disclosure requirements in an effort to help financial statement users better understand the nature, amount, timing, and uncertainty of revenue that is recognized. ASC 606 will be effective for our annual reporting period beginning on January 1, 2018, including interim periods within that year. ASC 606 may be applied retrospectively to each period presented or on a modified retrospective basis with the cumulative effect recognized as of the date of adoption. We are currently assessing the impact this guidance may have on our consolidated financial statements by analyzing our current portfolio of third-party payor contracts, including a review of historical accounting policies and practices to identify potential differences in applying the new guidance. We are also evaluating the nature and amount of data available to us in assessing implementation of ASC 606. Under ASC 606, substantially all amounts that were previously presented as Provision for doubtful accounts will be considered an implicit price concession in determining Net operating revenues . Amounts considered to be doubtful accounts under ASC 606 will be presented as a component of Total operating expenses within the consolidated statements of operations. Except for the adjustments discussed above, we do not expect the adoption of ASC 606 to have a material impact on our consolidated financial statements. We expect to adopt ASC 606 retrospectively effective January 1, 2018. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Topic 825): Recognition and Measurement of Financial Assets and Financial Liabilities.” This standard revises the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value. This revised standard requires the change in fair value of many equity investments to be recognized in Net income . This revised standard requires a modified retrospective application with a cumulative effect adjustment recognized in retained earnings as of the date of adoption and is effective for our interim and annual periods beginning January 1, 2018. While we are currently assessing the impact this guidance may have on our consolidated financial statements, we expect to recognize mark-to-market gains and losses associated with our available-for-sale equity securities through Net income instead of Accumulated other comprehensive income . We continue to review the requirements of this revised standard, but do not expect the adoption of this guidance to have a material impact on our consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” in order to increase transparency and comparability by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new standard, lessees will recognize a right-of-use asset and a corresponding lease liability for all leases other than leases that meet the definition of a short-term lease. The liability will be equal to the present value of future minimum lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in an expense pattern similar to current capital leases. Classification will be based on criteria that are similar to those applied in current lease accounting. This standard will be effective for our annual reporting period beginning on January 1, 2019. Early adoption is permitted. In transition, we will be required to recognize and measure leases beginning in the earliest period presented using a modified retrospective approach; therefore, we anticipate restating our consolidated financial statements for the two fiscal years prior to the year of adoption. While we are currently assessing the impact this guidance may have on our consolidated financial statements, we expect that virtually all of our existing operating leases will be reflected as right-of-use assets and liabilities on our consolidated balance sheets under the new standard. We do not expect to early adopt this standard. See Note 6, Property and Equipment , to the consolidated financial statements accompanying the 2016 Form 10-K for disclosure related to our operating leases. In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting (Topic 718),” to simplify various aspects of share-based payment accounting and presentation. The new standard requires entities to record all of the tax effects related to share-based payments at settlement (or expiration) through the income statement. This change is required to be applied prospectively to all excess tax benefits and tax deficiencies resulting from settlements after the date of adoption of the ASU. The standard eliminates the requirement to delay recognition of a windfall tax benefit until it reduces current taxes payable. This change is required to be applied on a modified retrospective basis. In addition, all income tax-related cash flows resulting from share-based windfall tax benefits are required to be reported as operating activities on the statement of cash flows as opposed to the current presentation as an inflow from financing activities and an outflow from operating activities. Either prospective or retrospective transition of this provision is permitted. The standard also clarifies that all cash payments made to taxing authorities on the employees’ behalf for withheld shares should be presented as financing activities on the statement of cash flows on a retrospective basis. Finally, the standard allows entities to make an accounting policy election to either estimate forfeitures for each period or account for forfeitures as they occur. For HealthSouth, this guidance was effective for its annual reporting period beginning January 1, 2017, including interim periods within that reporting period. As a result of our adoption of this guidance effective January 1, 2017, we recorded $0.4 million and $9.0 million of tax benefits in excess of compensation cost (“windfalls”) to Provision for income tax expense in our condensed consolidating statement of operations for the three and nine months ended September 30, 2017 , respectively . In addition, we elected to retrospectively apply the guidance governing presentation of windfalls on the statement of cash flows, which resulted in a reclassification of windfalls of $17.3 million from Cash flows from financing activities to Cash flows from operating activities for the year ended December 31, 2016 within our 2016 Form 10-K . We also retrospectively applied the change to the presentation of cash payments made to taxing authorities on the employees’ behalf for withheld shares on our condensed consolidating statements of cash flows for the nine months ended September 30, 2016, which resulted in a reclassification of $9.9 million from Cash flows from operating activities to Cash flows from financing activities . We did not elect an accounting policy change to record forfeitures as they occur and thus will continue to estimate forfeitures at each period. Except for the adjustments discussed above, the adoption of this guidance did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326),” which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance is effective for HealthSouth for the annual period beginning January 1, 2020, including interim periods within that reporting period. Early adoption is permitted for HealthSouth beginning January 1, 2019. We continue to review the requirements of this standard and any potential impact it may have on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments,” to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. In addition, the standard clarifies when cash receipts and cash payments have aspects of more than one class of cash flows and cannot be separated, classification will depend on the predominant source or use. The new guidance requires retrospective application and is effective for HealthSouth for the annual reporting period beginning January 1, 2018, including interim periods within that reporting period. Early adoption is permitted. While we continue to review the requirements of this standard and any potential impact it may have on our consolidated financial statements, the clarification that debt prepayment premiums should be classified as financing activities will result in an immaterial increase in certain prior period operating cash inflows and a corresponding increase in financing cash outflows. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230), Restricted Cash,” to clarify how entities should present restricted cash and restricted cash equivalents in the statement of cash flows. The new guidance requires amounts generally described as restricted cash and restricted cash equivalents be included with Cash and cash equivalents when reconciling the total beginning and ending amounts for the periods shown on the statement of cash flows. The new guidance requires retrospective application and is effective for our annual reporting period beginning January 1, 2018, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this revised standard and any potential impact it may have on our consolidated financial statements. We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Business Combinations	Business Combinations Inpatient Rehabilitation During the nine months ended September 30, 2017 , we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas. • In April 2017, we acquired 80% of Memorial Hospital at Gulfport, a 33 -bed inpatient rehabilitation hospital in Gulfport, Mississippi, through a joint venture with Memorial Hospital at Gulfport. This acquisition was funded on March 31, 2017 using cash on hand. • In April 2017, we also acquired approximately 80% of Mount Carmel West, an inpatient rehabilitation unit in Columbus, Ohio, through a joint venture with Mount Carmel Health System. This acquisition was funded through a contribution of a 60 ‑bed de novo inpatient rehabilitation hospital to the consolidated joint venture. • In July 2017, we acquired 50% of the inpatient rehabilitation unit at Jackson-Madison County General Hospital through a joint venture with West Tennessee Healthcare. The acquisition was funded through a contribution of our existing inpatient rehabilitation hospital in Martin, Tennessee to the consolidated joint venture. • In September 2017, we acquired 75% of Heritage Valley Beaver Hospital’s inpatient rehabilitation unit in Beaver, Pennsylvania, through a joint venture with Heritage Valley Health System, Inc. The acquisition was funded through the exchange of 25% of our existing inpatient rehabilitation hospital in Sewickley, Pennsylvania. We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from their respective dates of acquisition. Assets acquired were recorded at their estimated fair values as of the respective acquisition dates. The fair values of the identifiable intangible assets were based on valuations using the income approach. The income approach is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital’s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. None of the goodwill recorded as a result of these transactions is deductible for federal income tax purposes. The fair value of the assets acquired at the acquisition date were as follows (in millions): Property and equipment $ 0.1 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 3 years) 0.6 Trade name (useful life of 20 years) 0.5 Certificate of need (useful life of 20 years) 9.8 Goodwill 24.0 Total assets acquired $ 35.0 Information regarding the net cash paid for the inpatient rehabilitation acquisitions during each period presented is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Fair value of assets acquired $ 5.4 $ 1.4 $ 11.0 $ 6.7 Goodwill 9.0 7.6 24.0 9.4 Fair value of noncontrolling interest owned by joint venture partner (14.4 ) (9.0 ) (24.1 ) (16.1 ) Net cash paid for acquisition $ — $ — $ 10.9 $ — Home Health and Hospice During the nine months ended September 30, 2017 , we completed the following home health acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide post-acute healthcare services to patients in the applicable geographic areas. Each acquisition was funded using cash on hand. • In February 2017, we acquired the assets of Celtic Healthcare of Maryland, Inc., a home health provider with locations in Owings Mill, Maryland and Rockville, Maryland. • In February 2017, we also acquired the assets of two home health locations from Community Health Services, Inc., located in Owensboro, Kentucky and Elizabethtown, Kentucky. • In May 2017, we acquired the assets of two home health locations from Bio Care Home Health Services, Inc. and Kinsman Enterprises, Inc., located in Irving, Texas and Longview, Texas. • In July 2017, we acquired the assets of four home health locations from VNA Healthtrends, located in Bourbonnais, Illinois; Des Plaines, Illinois; Schererville, Indiana; and Tempe, Arizona. • In August 2017, we acquired the assets of two home health locations from VNA Healthtrends, located in Canton, Ohio and Forsyth, Illinois. We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired locations from their respective dates of acquisition. Assets acquired or liabilities assumed were recorded at their estimated fair values as of the respective acquisition dates. The fair values of identifiable intangible assets were based on valuations using the cost and income approaches. The cost approach is based on amounts that would be required to replace the asset (i.e., replacement cost). The income approach is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to utilize the acquired locations’ mobile workforce and established relationships within each community and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. All goodwill recorded as a result of these transactions is deductible for federal income tax purposes. The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions): Total current assets $ 0.1 Identifiable intangible asset: Noncompete agreements (useful lives of 5 years) 0.7 Trade name (useful life of 1 year) 0.1 Certificates of need (useful lives of 10 years) 0.7 Licenses (useful lives of 10 years) 3.8 Goodwill 20.5 Total assets acquired 25.9 Total liabilities assumed (0.2 ) Net assets acquired $ 25.7 Information regarding the net cash paid for the home health acquisitions during each period presented is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Fair value of assets acquired $ 2.7 $ 1.9 $ 5.4 $ 3.4 Goodwill 13.1 8.3 20.5 16.3 Fair value of liabilities assumed (0.1 ) — (0.2 ) (0.1 ) Net cash paid for acquisitions $ 15.7 $ 10.2 $ 25.7 $ 19.6 Pro Forma Results of Operations The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2016 (in millions): Net Operating Revenues Net Income Attributable to HealthSouth Acquired entities only: Actual from acquisition date to September 30, 2017 $ 17.5 $ (5.9 ) Combined entity: Supplemental pro forma from 07/01/2017-09/30/2017 996.1 65.9 Combined entity: Supplemental pro forma from 07/01/2016-09/30/2016 942.3 63.5 Combined entity: Supplemental pro forma from 01/01/2017-09/30/2017 2,975.9 198.4 Combined entity: Supplemental pro forma from 01/01/2016-09/30/2016 2,805.3 188.1 See Note 2, Business Combinations , to the consolidated financial statements accompanying the 2016 Form 10-K for information regarding acquisitions completed in 2016.

Variable Interest Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities As of September 30, 2017 and December 31, 2016, we consolidated ten limited partnership-like entities that are variable interest entities (“VIEs”) and of which we are the primary beneficiary. Our ownership percentages in these entities range from 6.8% to 99.5% . Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities. The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions): September 30, 2017 December 31, 2016 Assets Current assets: Cash and cash equivalents $ 1.8 $ 1.6 Accounts receivable, net of allowance for doubtful accounts 30.0 30.8 Other current assets 5.6 5.8 Total current assets 37.4 38.2 Property and equipment, net 143.1 140.0 Goodwill 73.5 73.5 Intangible assets, net 7.6 9.6 Other long-term assets 1.1 1.0 Total assets $ 262.7 $ 262.3 Liabilities Current liabilities: Current portion of long-term debt $ 1.7 $ 1.5 Accounts payable 6.9 6.8 Accrued expenses and other current liabilities 16.6 12.2 Total current liabilities 25.2 20.5 Long-term debt, net of current portion 28.7 29.8 Total liabilities $ 53.9 $ 50.3

Investments in and Advances to

Investments in and Advances to Nonconsolidated Affiliates	9 Months Ended
	Sep. 30, 2017
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Investments in and Advances to Nonconsolidated Affiliates	Investments in and Advances to Nonconsolidated Affiliates As of September 30, 2017 and December 31, 2016 , we had $12.6 million and $13.0 million , respectively, of investments in and advances to nonconsolidated affiliates included in Other long-term assets in our condensed consolidated balance sheets. Investments in and advances to nonconsolidated affiliates represent our investments in seven partially owned subsidiaries, of which six are general or limited partnerships, limited liability companies, or joint ventures in which HealthSouth or one of its subsidiaries is a general or limited partner, managing member, member, or venturer, as applicable. We do not control these affiliates but have the ability to exercise significant influence over the operating and financial policies of certain of these affiliates. Our ownership percentages in these affiliates range from approximately 1% to 60% . We account for these investments using the cost and equity methods of accounting. The following summarizes the combined results of operations of our equity method affiliates (on a 100% basis, in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net operating revenues $ 9.9 $ 11.3 $ 31.0 $ 33.4 Operating expenses (5.6 ) (6.0 ) (18.1 ) (18.1 ) Income from continuing operations, net of tax 4.3 5.2 12.9 15.2 Net income 4.3 5.2 12.9 15.2

Long-term Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt Our long-term debt outstanding consists of the following (in millions): September 30, 2017 December 31, 2016 Credit Agreement— Advances under revolving credit facility $ 138.0 $ 152.0 Term loan facilities 298.3 421.2 Bonds payable— 5.125% Senior Notes due 2023 295.7 295.3 5.75% Senior Notes due 2024 1,193.7 1,193.2 5.75% Senior Notes due 2025 344.3 343.9 2.00% Convertible Senior Subordinated Notes due 2043 — 275.7 Other notes payable 80.1 55.8 Capital lease obligations 272.3 279.3 2,622.4 3,016.4 Less: Current portion (31.1 ) (37.1 ) Long-term debt, net of current portion $ 2,591.3 $ 2,979.3 The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions): Face Amount Net Amount October 1 through December 31, 2017 $ 7.4 $ 7.4 2018 31.6 31.6 2019 31.7 31.6 2020 24.4 24.4 2021 25.8 25.8 2022 399.2 397.4 Thereafter 2,120.4 2,104.2 Total $ 2,640.5 $ 2,622.4 In May 2017, we provided notice of our intent to exercise our early redemption option on the $320 million outstanding principal amount of the 2.00% Convertible Senior Subordinated Notes due 2043 (the “Convertible Notes”). Pursuant to the indenture, the holders had the right to convert their Convertible Notes into shares of our common stock at a conversion rate of 27.2221 shares per $1,000 principal amount of Convertible Notes, which rate was increased by the make-whole premium. Holders of $319.4 million in principal of these Convertible Notes chose to convert their notes to shares of our common stock resulting in the issuance of 8.9 million shares from treasury stock, including 0.2 million shares due to the make-whole premium. Approximately 8.6 million of these shares were included in Diluted earnings per share attributable to HealthSouth common shareholders as of March 31, 2017 . We redeemed the remaining $0.6 million in principal at par in cash. The redemption and all conversions occurred in the second quarter of 2017. As a result of these transactions, we recorded a $10.4 million Loss on early extinguishment of debt in the second quarter of 2017. See also Note 10, Earnings per Common Share for additional information on these Convertible Notes. In September 2017, we amended our existing credit agreement. The following are the changes made to the material provisions of the credit agreement: • increase the maximum capacity under the revolving credit facility from $600 million to $700 million ; • decrease the current term loan facility to $300 million with a net repayment of approximately $110 million ; • decrease the spread used to calculate the applicable interest rate on any outstanding revolving credit or term loan balances by 25 basis points; • in addition to the specified amounts and types of permitted investments, allow for additional investments so long as the senior secured leverage ratio is no greater than 2.00:1 after giving pro forma effect to those additional investments; • in addition to the specified amounts and types of permitted restricted payments, allow for additional restricted payments so long as the senior secured leverage ratio is no greater than 2.00:1 (rather than the 1.75:1 threshold ratio applicable to this provision previously) after giving pro forma effect to those additional restricted payments; • increase the maximum amount of permitted capital expenditures in a given year from $300 million to $350 million , which amount is in addition to any unused portion of the permitted amount from the prior year; • increase the maximum leverage ratio in the financial covenants applicable for the periods ending on or before September 30, 2019 from 4.25x to 4.50x ; • increase the accordion feature permitting future increases in revolving borrowing capacity or new term loans, or both, from an aggregate amount not to exceed $300 million to the greater of (a) $870 million and (b) our adjusted consolidated EBITDA for the most recently completed four-quarter period, after giving pro forma effect to any additional borrowings; and • move the maturity date for both the revolving credit and term loan facilities from July 2020 to September 2022. All other material terms of the existing credit agreement remained the same and are described in more detail in Note 9, Long-term Debt , to the consolidated financial statements accompanying the 2016 Form 10-K. As a result of this amendment, we recorded a $0.3 million Loss on early extinguishment of debt in the third quarter of 2017. In February 2016, we entered into a development/lease agreement with CR HQ, LLC (the “Developer”) to construct our new corporate headquarters in Birmingham, Alabama. Under the terms of this agreement, the Developer is responsible for all costs of constructing the new facility ‘shell’ which will then be leased to us for an initial term of 15 years with four , five -year renewal options. The lease is expected to commence in the first half of 2018. We are responsible for the costs associated with improvements to the interior of the building. Due to the nature and extent of the tenant improvements we will be making to the new corporate headquarters and certain provisions of the development/lease agreement, we are deemed to be the accounting owner of the new corporate headquarters during the construction period. Construction commenced in the second quarter of 2016. As of September 30, 2017 and December 31, 2016 , Property and equipment, net includes $46.8 million and $20.3 million , respectively, for the construction costs incurred to date by the Developer, and Long-term debt, net of current portion includes a corresponding financing obligation liability of $46.6 million and $20.3 million , respectively. The remaining corresponding financing obligation liability of $0.2 million as of September 30, 2017 is included in Current portion of long-term debt . It is estimated that the total financing obligation associated with the Developer’s costs to construct the new corporate headquarters will be $56 million . The amounts recorded for construction costs and the corresponding liability are noncash activities for purposes of our condensed consolidated statement of cash flows. For additional information regarding our indebtedness, see Note 9, Long-term Debt, to the consolidated financial statements accompanying the 2016 Form 10-K .

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	9 Months Ended
	Sep. 30, 2017
Noncontrolling Interest [Abstract]
Redeemable Noncontolling Interests	Redeemable Noncontrolling Interests The following is a summary of the activity related to our Redeemable noncontrolling interests during the nine months ended September 30, 2017 and 2016 (in millions): Nine Months Ended September 30, 2017 2016 Balance at beginning of period $ 138.3 $ 121.1 Net income attributable to noncontrolling interests 9.9 11.2 Distributions declared (3.3 ) (6.4 ) Contribution to joint venture 2.3 — Change in fair value 74.1 (16.5 ) Balance at end of period $ 221.3 $ 109.4 The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016 (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net income attributable to nonredeemable noncontrolling interests $ 15.0 $ 12.7 $ 43.3 $ 42.5 Net income attributable to redeemable noncontrolling interests 4.2 3.7 9.9 11.2 Net income attributable to noncontrolling interests $ 19.2 $ 16.4 $ 53.2 $ 53.7 See also Note 7, Fair Value Measurements .

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of September 30, 2017 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Valuation Technique (1) Other current assets: Current portion of restricted marketable securities $ 18.5 $ — $ 18.5 $ — M Other long-term assets: Restricted marketable securities 41.4 — 41.4 — M Redeemable noncontrolling interests 221.3 — — 221.3 I As of December 31, 2016 Other current assets: Current portion of restricted marketable securities $ 24.2 $ — $ 24.2 $ — M Other long-term assets: Restricted marketable securities 33.5 — 33.5 — M Redeemable noncontrolling interests 138.3 — — 138.3 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I). The fair values of our financial assets and liabilities are determined as follows: • Restricted marketable securities - The fair values of our available-for-sale restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active. • Redeemable noncontrolling interests - The fair value of the Redeemable noncontrolling interest related to our home health segment is determined using the product of a twelve-month specified performance measure and a specified median market price multiple based on a basket of public health companies. To determine the fair value of the Redeemable noncontrolling interests in our joint venture hospitals, we use the applicable hospitals’ projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable facilities. The projected operating results use management’s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures. See also Note 6 , Redeemable Noncontrolling Interests . In addition to assets and liabilities recorded at fair value on a recurring basis, we are also required to record assets and liabilities at fair value on a nonrecurring basis. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or similar adjustments made to the carrying value of the applicable assets. During the three and nine months ended September 30, 2017 and September 30, 2016 , we did not record any gains or losses related to our nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis as part of our continuing operations. As discussed in Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” to the consolidated financial statements accompanying the 2016 Form 10-K , the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions): As of September 30, 2017 As of December 31, 2016 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 138.0 $ 138.0 $ 152.0 $ 152.0 Term loan facilities 298.3 300.0 421.2 422.5 5.125% Senior Notes due 2023 295.7 310.0 295.3 297.8 5.75% Senior Notes due 2024 1,193.7 1,231.5 1,193.2 1,216.6 5.75% Senior Notes due 2025 344.3 365.8 343.9 349.6 2.00% Convertible Senior Subordinated Notes due 2043 — — 275.7 382.6 Other notes payable 80.1 80.1 55.8 55.8 Financial commitments: Letters of credit — 35.4 — 33.3 Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies , “Fair Value Measurements,” to the consolidated financial statements accompanying the 2016 Form 10-K .

Share-Based Payments

Share-Based Payments	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Payments	Share-Based Payments In February and May 2017, we issued a total of 0.6 million restricted stock awards to members of our management team and our board of directors. Approximately 0.2 million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company’s performance during the applicable two -year performance measurement period. Additionally, in February 2017, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note 1, Summary of Significant Accounting Policies , and Note 13, Share-Based Payments , to the consolidated financial statements accompanying the 2016 Form 10-K .

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our Provision for income tax expense of $43.1 million for the three months ended September 30, 2017 primarily resulted from the application of our estimated effective blended federal and state income tax rate. Our Provision for income tax expense of $111.4 million for the nine months ended September 30, 2017 primarily resulted from the application of our estimated effective blended federal and state income tax rate as well as tax benefits resulting from exercises and vesting of share-based compensation. Our Provision for income tax expense of $42.1 million and $124.2 million for the three and nine months ended September 30, 2016 , respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate. We have state net operating losses (“NOLs”) of $62.0 million that expire in various amounts at varying times through 2031 . The $91.6 million of net deferred tax assets included in the accompanying condensed consolidated balance sheet as of September 30, 2017 reflects management’s assessment it is more likely than not we will be able to generate sufficient future taxable income to utilize those deferred tax assets based on our current estimates and assumptions. As of September 30, 2017 , we maintained a valuation allowance of $28.4 million due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management’s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, or if the timing of future tax deductions differs from our expectations. During the third quarter of 2016, we filed a non-automatic tax accounting method change related to billings denied under pre-payment claims reviews conducted by certain of our Medicare Administrative Contractors. In March 2017, the IRS approved our request resulting in additional tax benefits of approximately $55 million through September 30, 2017 . Approximately $39 million of this amount represents pre-payment claims denials received in years prior to and including the year ended December 31, 2015. These benefits are expected to reverse as pre-payment claims denials are settled and collected. This change did not have a material impact on our effective tax rate. Total remaining gross unrecognized tax benefits were $0.3 million and $2.8 million as of September 30, 2017 and December 31, 2016 , respectively, all of which would affect our effective tax rate if recognized. A reconciliation of the beginning and ending liability for unrecognized tax benefits is as follows (in millions): Gross Unrecognized Income Tax Benefits Balance at December 31, 2016 $ 2.8 Gross amount of decreases in unrecognized tax benefits related to prior periods (0.4 ) Decreases in unrecognized tax benefits relating to settlements with taxing authorities (2.1 ) Balance at September 30, 2017 $ 0.3 Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during the three and nine months ended September 30, 2017 and 2016 was not material. Accrued interest income related to income taxes as of September 30, 2017 and December 31, 2016 was not material. In December 2014, we signed an agreement with the IRS to begin participating in their Compliance Assurance Process, a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax return. We renewed this agreement in December 2015 for the 2016 tax year and in December 2016 for the 2017 tax year. As a result of these agreements, the IRS surveyed our 2013, 2012, and 2011 federal income tax returns and is currently examinin g 2016 and 2017. Our 2014 federal income tax return has been filed, and the IRS has not indicated its intent to examine or survey this return. In February 2017, the IRS issued a no-change Revenue Agent’s Report effectively closing our 2015 tax audit. We have settled federal income tax examinations with the IRS for all tax years throu gh 2013 as well as 2015. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by three states for tax years ranging from 2012 through 2015. For the tax years that remain open under the applicable statutes of limitation, amounts related to unrecognized tax benefits have been considered by management in its estimate of our potential net recovery of prior years’ income taxes. Based on discussions with taxing authorities, we do not anticipate that any of our unrecognized tax benefits will be released within the next 12 months.

Earnings per Common Share

Earnings per Common Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Earnings per Common Share	Earnings per Common Share The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic: Numerator: Income from continuing operations $ 85.2 $ 78.2 $ 249.1 $ 236.3 Less: Net income attributable to noncontrolling interests included in continuing operations (19.2 ) (16.4 ) (53.2 ) (53.7 ) Less: Income allocated to participating securities (0.2 ) (0.2 ) (0.6 ) (0.6 ) Income from continuing operations attributable to HealthSouth common shareholders 65.8 61.6 195.3 182.0 Loss from discontinued operations, net of tax, attributable to HealthSouth common shareholders (0.1 ) (0.1 ) (0.2 ) (0.3 ) Net income attributable to HealthSouth common shareholders $ 65.7 $ 61.5 $ 195.1 $ 181.7 Denominator: Basic weighted average common shares outstanding 97.8 89.1 92.3 89.3 Basic earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.67 $ 0.69 $ 2.11 $ 2.03 Discontinued operations — — — — Net income $ 0.67 $ 0.69 $ 2.11 $ 2.03 Diluted: Numerator: Income from continuing operations $ 85.2 $ 78.2 $ 249.1 $ 236.3 Less: Net income attributable to noncontrolling interests included in continuing operations (19.2 ) (16.4 ) (53.2 ) (53.7 ) Add: Interest on convertible debt, net of tax — 2.4 4.6 7.2 Add: Loss on extinguishment of convertible debt, net of tax — — 6.2 — Income from continuing operations attributable to HealthSouth common shareholders 66.0 64.2 206.7 189.8 Loss from discontinued operations, net of tax, attributable to HealthSouth common shareholders (0.1 ) (0.1 ) (0.2 ) (0.3 ) Net income attributable to HealthSouth common shareholders $ 65.9 $ 64.1 $ 206.5 $ 189.5 Denominator: Diluted weighted average common shares outstanding 99.0 99.4 99.1 99.5 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.67 $ 0.64 $ 2.08 $ 1.90 Discontinued operations — — — — Net income $ 0.67 $ 0.64 $ 2.08 $ 1.90 The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic weighted average common shares outstanding 97.8 89.1 92.3 89.3 Convertible senior subordinated notes — 8.5 5.4 8.5 Restricted stock awards, dilutive stock options, and restricted stock units 1.2 1.8 1.4 1.7 Diluted weighted average common shares outstanding 99.0 99.4 99.1 99.5 In October 2016, February 2017, and May 2017, our board of directors declared cash dividends of $0.24 per share that were paid in January 2017, April 2017, and July 2017, respectively. On July 20, 2017, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.25 per share that was paid on October 16, 2017 to stockholders of record on October 2, 2017. On October 20, 2017, our board of directors declared a cash dividend of $0.25 per share, payable on January 16, 2018 to stockholders of record on January 2, 2018. As of September 30, 2017 and December 31, 2016 , accrued common stock dividends of $25.3 million and $22.2 million , respectively, were included in Accrued expenses and other current liabilities in our condensed consolidated balance sheets. Future dividend payments are subject to declaration by our board of directors. On September 30, 2009, we issued 5.0 million shares of common stock and 8.2 million common stock warrants in full satisfaction of our obligation to do so under the January 2007 comprehensive settlement of the consolidated securities action brought against us by our stockholders and bondholders. Under the terms of the related warrant agreement, the warrants were exercisable at a price of $41.40 per share by means of a cash or a cashless exercise at the option of the holder. The warrants were not assumed exercised for dilutive shares outstanding because they were antidilutive in the periods presented. The warrants expired on January 17, 2017. The following table summarizes information relating to these warrants and their activity through their expiration date (number of warrants in millions): Number of Warrants Weighted-Average Exercise Price Common stock warrants outstanding as of December 31, 2016 8.2 $ 41.40 Cashless exercise (6.5 ) 41.40 Cash exercise (0.6 ) 41.40 Expired (1.1 ) 41.40 Common stock warrants outstanding as of January 17, 2017 — The above exercises resulted in the issuance of 0.7 million shares of common stock. Cash exercises resulted in gross proceeds of approximately $27 million . See Note 9, Long-term Debt and Note 16, Earnings per Common Share , to the consolidated financial statements accompanying the 2016 Form 10-K for additional information related to our Convertible Notes, common stock, common stock warrants, and convertible perpetual preferred stock.

Contingencies and Other Commitm

Contingencies and Other Commitments	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Commitments	Contingencies and Other Commitments We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. Nichols Litigation— We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned Nichols v. HealthSouth Corp . The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs’ counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of the former officers named as a defendant has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On November 25, 2014, the plaintiffs filed another amended complaint to assert new allegations relating to the time period of 1997 to 2002. On December 10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lack standing because their claims are derivative in nature, and the claims are time-barred by the statute of limitations. On May 26, 2016, the court granted our motion to dismiss. The plaintiffs appealed the dismissal of the case to the Supreme Court of Alabama on June 28, 2016. The Supreme Court has not yet scheduled a hearing on the appeal. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate an amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. Other Litigation— One of our hospital subsidiaries was named as a defendant in a lawsuit filed August 12, 2013 by an individual in the Circuit Court of Etowah County, Alabama, captioned Honts v. HealthSouth Rehabilitation Hospital of Gadsden, LLC. The plaintiff alleged that her mother, who died more than three months after being discharged from our hospital, received an unprescribed opiate medication at the hospital. We deny the patient received any such medication, accounted for all the opiates at the hospital and argued the plaintiff established no causal liability between the actions of our staff and her mother’s death. The plaintiff sought recovery for punitive damages. On May 18, 2016, the jury in this case returned a verdict in favor of the plaintiff for $20.0 million . On June 17, 2016, we filed a renewed motion for judgment as a matter of law or, in the alternative, a motion for new trial or, in the further alternative, a motion seeking reduction of the damages awarded (collectively, the “post-judgment motions”). The trial court denied the post-judgment motions. We appealed the verdict as well as the rulings on the post-judgment motions to the Supreme Court of Alabama on October 12, 2016. The Supreme Court scheduled an oral hearing on the appeal for November 8, 2017. We posted a bond in the amount of the judgment pending resolution of our appeal. We intend to vigorously defend ourselves in this case. Although we continue to believe in the merit of our defenses and counterarguments, we recorded a net charge of $5.7 million to Other operating expenses in our consolidated statements of operations for the year ended December 31, 2016. As of September 30, 2017, we maintained a liability of $20.2 million in Accrued expenses and other liabilities in our condensed consolidated balance sheet with a corresponding receivable of $15.5 million in Other current assets for the portion of the liability we would expect to be covered through our excess insurance coverages. The portion of this liability that would be a covered claim through our captive insurance subsidiary, HCS, Ltd. is $6.0 million . Governmental Inquiries and Investigations— On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital (“LTCH”) we closed in August 2011, and issued from the Dallas, Texas office of the United States Department of Health and Human Services Office of Inspector General (“HHS-OIG”). The subpoena stated it was in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requested documents and materials relating to patient admissions, length of stay, and discharge matters at this closed LTCH. We furnished the documents requested and have heard nothing from the HHS-OIG since December 2012. On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to four of our hospitals. Those subpoenas also requested complete copies of medical records for 100 patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the “DOJ”). On April 24, 2014, we received document subpoenas relating to an additional seven of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. Two of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The most recent subpoenas do not include requests for specific patient files. However, in February 2015, the DOJ requested the voluntary production of the medical records of an additional 70 patients, some of whom were treated in hospitals not subject to the subpoenas, and we provided these records. We have not received any subsequent requests for medical records from the DOJ. All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and request documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare 60% rule. Under the Medicare rule commonly referred to as the “ 60% rule,” an inpatient rehabilitation hospital must treat 60% or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. We are cooperating fully with the DOJ in connection with this investigation and are currently unable to predict the timing or outcome of it. We intend to vigorously defend ourselves in this matter. Based on discussions with the DOJ, review of the current facts and circumstances as we understand them, and the nature of the investigation, it is not possible to estimate an amount of loss, if any, or range of possible loss that might result from it. Other Matters— The False Claims Act allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These qui tam cases are sealed by the court at the time of filing. Prior to the release of the seal by the presiding court, the only parties typically privy to the information contained in the complaint are the relator, the federal government, and the court. It is possible that qui tam lawsuits have been filed against us and that those suits remain under seal or that we are unaware of such filings or prevented by existing law, or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed qui tam cases brought pursuant to the False Claims Act. It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and the United States Centers for Medicare and Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting Our internal financial reporting and management structure is focused on the major types of services provided by HealthSouth. We manage our operations using two operating segments which are also our reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments: • Inpatient Rehabilitation - Our national network of inpatient rehabilitation hospitals stretches across 31 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of September 30, 2017 , we operate 126 inpatient rehabilitation hospitals, including one hospital that operates as a joint venture which we account for using the equity method of accounting. In addition, we manage four inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. • Home Health and Hospice - As of September 30, 2017 , we provide home health and hospice services in 235 locations across 28 states. Two of these home health locations operate as joint ventures which we account for using the equity method of accounting. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Our hospice services primarily include in-home services to terminally ill patients and their families to address patients’ physical needs, including pain control and symptom management, and to provide emotional and spiritual support. The accounting policies of our reportable segments are the same as those described in Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2016 Form 10-K . All revenues for our services are generated through external customers. See Note 1, Basis of Presentation , “Net Operating Revenues,” for the payor composition of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (“Segment Adjusted EBITDA”). Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 2017 2016 2017 2016 Net operating revenues $ 794.8 $ 751.7 $ 2,377.3 $ 2,253.5 $ 200.8 $ 175.1 $ 574.4 $ 503.8 Less: Provision for doubtful accounts (11.3 ) (13.7 ) (38.4 ) (43.8 ) (1.3 ) (1.1 ) (4.3 ) (2.9 ) Net operating revenues less provision for doubtful accounts 783.5 738.0 2,338.9 2,209.7 199.5 174.0 570.1 500.9 Operating expenses: Inpatient rehabilitation: Salaries and benefits 403.2 371.2 1,195.7 1,107.2 — — — — Other operating expenses 117.4 110.1 342.1 321.7 — — — — Supplies 33.1 31.9 100.6 96.1 — — — — Occupancy costs 15.7 15.0 46.3 46.0 — — — — Home health and hospice: Cost of services sold (excluding depreciation and amortization) — — — — 93.5 86.8 271.2 246.8 Support and overhead costs — — — — 68.9 59.5 203.4 174.5 569.4 528.2 1,684.7 1,571.0 162.4 146.3 474.6 421.3 Other income (1.0 ) (0.8 ) (2.9 ) (2.1 ) — — — — Equity in net income of nonconsolidated affiliates (1.9 ) (2.3 ) (5.6 ) (6.7 ) (0.2 ) (0.2 ) (0.6 ) (0.6 ) Noncontrolling interests 16.7 14.3 48.6 47.9 2.5 2.1 4.6 5.8 Segment Adjusted EBITDA $ 200.3 $ 198.6 $ 614.1 $ 599.6 $ 34.8 $ 25.8 $ 91.5 $ 74.4 Capital expenditures $ 59.1 $ 42.7 $ 164.7 $ 128.9 $ 1.7 $ 2.2 $ 5.6 $ 4.6 Inpatient Rehabilitation Home Health and Hospice HealthSouth Consolidated As of September 30, 2017 Total assets $ 3,812.4 $ 1,141.4 $ 4,883.4 Investments in and advances to nonconsolidated affiliates 10.0 2.6 12.6 As of December 31, 2016 Total assets $ 3,629.6 $ 1,123.7 $ 4,681.9 Investments in and advances to nonconsolidated affiliates 10.6 2.4 13.0 Segment reconciliations (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total segment Adjusted EBITDA $ 235.1 $ 224.4 $ 705.6 $ 674.0 General and administrative expenses (39.7 ) (30.3 ) (128.6 ) (96.6 ) Depreciation and amortization (46.2 ) (43.5 ) (137.2 ) (128.8 ) Loss on disposal of assets (3.0 ) (1.6 ) (3.3 ) (2.0 ) Professional fees—accounting, tax, and legal — — — (1.9 ) Loss on early extinguishment of debt (0.3 ) (2.6 ) (10.7 ) (7.4 ) Interest expense and amortization of debt discounts and fees (36.8 ) (42.5 ) (118.5 ) (130.5 ) Net income attributable to noncontrolling interests 19.2 16.4 53.2 53.7 Income from continuing operations before income tax expense $ 128.3 $ 120.3 $ 360.5 $ 360.5 September 30, 2017 December 31, 2016 Total assets for reportable segments $ 4,953.8 $ 4,753.3 Reclassification of deferred income tax liabilities to net deferred income tax assets (70.4 ) (71.4 ) Total consolidated assets $ 4,883.4 $ 4,681.9 Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Inpatient rehabilitation: Inpatient $ 768.6 $ 724.1 $ 2,297.7 $ 2,164.6 Outpatient and other 26.2 27.6 79.6 88.9 Total inpatient rehabilitation 794.8 751.7 2,377.3 2,253.5 Home health and hospice: Home health 181.2 162.0 519.4 470.0 Hospice 19.6 13.1 55.0 33.8 Total home health and hospice 200.8 175.1 574.4 503.8 Total net operating revenues $ 995.6 $ 926.8 $ 2,951.7 $ 2,757.3

Condensed Consolidating Financi

Condensed Consolidating Financial Information	9 Months Ended
	Sep. 30, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Financial Information	Condensed Consolidating Financial Information The accompanying condensed consolidating financial information has been prepared and presented pursuant to SEC Regulation S-X, Rule 3-10, “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” Each of the subsidiary guarantors is 100% owned by HealthSouth, and all guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. HealthSouth’s investments in its consolidated subsidiaries, as well as guarantor subsidiaries’ investments in nonguarantor subsidiaries and nonguarantor subsidiaries’ investments in guarantor subsidiaries, are presented under the equity method of accounting with the related investment presented within the line items Intercompany receivable and investments in consolidated affiliates and Intercompany payable in the accompanying condensed consolidating balance sheets. The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement and (2) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 2 x. The terms of our senior note indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2 x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture’s restricted payments covenant to declare and pay dividends. See Note 9, Long-term Debt , to the consolidated financial statements accompanying the 2016 Form 10-K . Periodically, certain wholly owned subsidiaries of HealthSouth make dividends or distributions of available cash and/or intercompany receivable balances to their parents. In addition, HealthSouth makes contributions to certain wholly owned subsidiaries. When made, these dividends, distributions, and contributions impact the Intercompany receivable and investments in consolidated affiliates , Intercompany payable , and HealthSouth shareholders’ equity line items in the accompanying condensed consolidating balance sheet but have no impact on the consolidated financial statements of HealthSouth Corporation. Three Months Ended September 30, 2017 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 5.3 $ 555.2 $ 466.5 $ (31.4 ) $ 995.6 Less: Provision for doubtful accounts — (7.7 ) (4.9 ) — (12.6 ) Net operating revenues less provision for doubtful accounts 5.3 547.5 461.6 (31.4 ) 983.0 Operating expenses: Salaries and benefits 9.1 266.4 271.9 (5.3 ) 542.1 Other operating expenses 8.0 83.6 58.2 (12.2 ) 137.6 Occupancy costs 0.4 23.4 8.7 (13.9 ) 18.6 Supplies — 22.4 14.1 — 36.5 General and administrative expenses 35.6 — 4.1 — 39.7 Depreciation and amortization 2.0 25.8 18.4 — 46.2 Total operating expenses 55.1 421.6 375.4 (31.4 ) 820.7 Loss on early extinguishment of debt 0.3 — — — 0.3 Interest expense and amortization of debt discounts and fees 30.8 5.3 6.3 (5.6 ) 36.8 Other income (5.7 ) (0.1 ) (0.8 ) 5.6 (1.0 ) Equity in net income of nonconsolidated affiliates — (1.9 ) (0.2 ) — (2.1 ) Equity in net income of consolidated affiliates (85.0 ) (11.8 ) — 96.8 — Management fees (35.8 ) 26.4 9.4 — — Income from continuing operations before income tax (benefit) expense 45.6 108.0 71.5 (96.8 ) 128.3 Provision for income tax (benefit) expense (20.4 ) 43.1 20.4 — 43.1 Income from continuing operations 66.0 64.9 51.1 (96.8 ) 85.2 Loss from discontinued operations, net of tax (0.1 ) — — — (0.1 ) Net income 65.9 64.9 51.1 (96.8 ) 85.1 Less: Net income attributable to noncontrolling interests — — (19.2 ) — (19.2 ) Net income attributable to HealthSouth $ 65.9 $ 64.9 $ 31.9 $ (96.8 ) $ 65.9 Comprehensive income $ 65.9 $ 64.9 $ 51.1 $ (96.8 ) $ 85.1 Comprehensive income attributable to HealthSouth $ 65.9 $ 64.9 $ 31.9 $ (96.8 ) $ 65.9 Three Months Ended September 30, 2016 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 4.9 $ 541.8 $ 409.8 $ (29.7 ) $ 926.8 Less: Provision for doubtful accounts — (10.0 ) (4.8 ) — (14.8 ) Net operating revenues less provision for doubtful accounts 4.9 531.8 405.0 (29.7 ) 912.0 Operating expenses: Salaries and benefits 10.4 250.2 241.4 (4.6 ) 497.4 Other operating expenses 6.4 79.4 52.3 (11.8 ) 126.3 Occupancy costs 0.6 22.4 7.9 (13.3 ) 17.6 Supplies — 22.4 12.4 — 34.8 General and administrative expenses 30.4 — (0.1 ) — 30.3 Depreciation and amortization 2.3 25.9 15.3 — 43.5 Total operating expenses 50.1 400.3 329.2 (29.7 ) 749.9 Loss on early extinguishment of debt 2.6 — — — 2.6 Interest expense and amortization of debt discounts and fees 36.3 5.4 5.8 (5.0 ) 42.5 Other income (5.1 ) (0.1 ) (0.6 ) 5.0 (0.8 ) Equity in net income of nonconsolidated affiliates — (2.3 ) (0.2 ) — (2.5 ) Equity in net income of consolidated affiliates (85.7 ) (9.8 ) — 95.5 — Management fees (33.9 ) 25.8 8.1 — — Income from continuing operations before income tax (benefit) expense 40.6 112.5 62.7 (95.5 ) 120.3 Provision for income tax (benefit) expense (21.2 ) 44.9 18.4 — 42.1 Income from continuing operations 61.8 67.6 44.3 (95.5 ) 78.2 Loss from discontinued operations, net of tax (0.1 ) — — — (0.1 ) Net income 61.7 67.6 44.3 (95.5 ) 78.1 Less: Net income attributable to noncontrolling interests — — (16.4 ) — (16.4 ) Net income attributable to HealthSouth $ 61.7 $ 67.6 $ 27.9 $ (95.5 ) $ 61.7 Comprehensive income $ 61.6 $ 67.6 $ 44.3 $ (95.5 ) $ 78.0 Comprehensive income attributable to HealthSouth $ 61.6 $ 67.6 $ 27.9 $ (95.5 ) $ 61.6 Nine Months Ended September 30, 2017 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 15.9 $ 1,693.9 $ 1,336.2 $ (94.3 ) $ 2,951.7 Less: Provision for doubtful accounts — (27.3 ) (15.4 ) — (42.7 ) Net operating revenues less provision for doubtful accounts 15.9 1,666.6 1,320.8 (94.3 ) 2,909.0 Operating expenses: Salaries and benefits 29.1 803.7 783.0 (15.8 ) 1,600.0 Other operating expenses 23.8 239.5 170.2 (36.3 ) 397.2 Occupancy costs 1.4 70.0 25.6 (42.2 ) 54.8 Supplies — 69.4 41.2 — 110.6 General and administrative expenses 104.7 — 23.9 — 128.6 Depreciation and amortization 6.7 77.3 53.2 — 137.2 Total operating expenses 165.7 1,259.9 1,097.1 (94.3 ) 2,428.4 Loss on early extinguishment of debt 10.7 — — — 10.7 Interest expense and amortization of debt discounts and fees 100.5 15.9 18.1 (16.0 ) 118.5 Other income (16.5 ) (0.2 ) (2.2 ) 16.0 (2.9 ) Equity in net income of nonconsolidated affiliates — (5.6 ) (0.6 ) — (6.2 ) Equity in net income of consolidated affiliates (256.4 ) (29.3 ) — 285.7 — Management fees (107.8 ) 80.7 27.1 — — Income from continuing operations before income tax (benefit) expense 119.7 345.2 181.3 (285.7 ) 360.5 Provision for income tax (benefit) expense (76.2 ) 137.7 49.9 — 111.4 Income from continuing operations 195.9 207.5 131.4 (285.7 ) 249.1 Loss from discontinued operations, net of tax (0.2 ) — — — (0.2 ) Net income 195.7 207.5 131.4 (285.7 ) 248.9 Less: Net income attributable to noncontrolling interests — — (53.2 ) — (53.2 ) Net income attributable to HealthSouth $ 195.7 $ 207.5 $ 78.2 $ (285.7 ) $ 195.7 Comprehensive income $ 196.0 $ 207.5 $ 131.4 $ (285.7 ) $ 249.2 Comprehensive income attributable to HealthSouth $ 196.0 $ 207.5 $ 78.2 $ (285.7 ) $ 196.0 Nine Months Ended September 30, 2016 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 14.9 $ 1,621.2 $ 1,209.2 $ (88.0 ) $ 2,757.3 Less: Provision for doubtful accounts — (32.1 ) (14.6 ) — (46.7 ) Net operating revenues less provision for doubtful accounts 14.9 1,589.1 1,194.6 (88.0 ) 2,710.6 Operating expenses: Salaries and benefits 32.7 746.4 704.2 (13.7 ) 1,469.6 Other operating expenses 18.9 230.1 152.4 (34.4 ) 367.0 Occupancy costs 2.4 67.2 23.8 (39.9 ) 53.5 Supplies — 67.1 37.1 — 104.2 General and administrative expenses 94.7 — 1.9 — 96.6 Depreciation and amortization 7.1 77.3 44.4 — 128.8 Professional fees—accounting, tax, and legal 1.9 — — — 1.9 Total operating expenses 157.7 1,188.1 963.8 (88.0 ) 2,221.6 Loss on early extinguishment of debt 7.4 — — — 7.4 Interest expense and amortization of debt discounts and fees 111.7 16.3 17.2 (14.7 ) 130.5 Other income (14.6 ) (0.2 ) (2.0 ) 14.7 (2.1 ) Equity in net income of nonconsolidated affiliates — (6.7 ) (0.6 ) — (7.3 ) Equity in net income of consolidated affiliates (259.7 ) (30.8 ) — 290.5 — Management fees (101.9 ) 77.0 24.9 — — Income from continuing operations before income tax (benefit) expense 114.3 345.4 191.3 (290.5 ) 360.5 Provision for income tax (benefit) expense (68.3 ) 137.8 54.7 — 124.2 Income from continuing operations 182.6 207.6 136.6 (290.5 ) 236.3 Loss from discontinued operations, net of tax (0.3 ) — — — (0.3 ) Net income 182.3 207.6 136.6 (290.5 ) 236.0 Less: Net income attributable to noncontrolling interests — — (53.7 ) — (53.7 ) Net income attributable to HealthSouth $ 182.3 $ 207.6 $ 82.9 $ (290.5 ) $ 182.3 Comprehensive income $ 182.5 $ 207.6 $ 136.6 $ (290.5 ) $ 236.2 Comprehensive income attributable to HealthSouth $ 182.5 $ 207.6 $ 82.9 $ (290.5 ) $ 182.5 As of September 30, 2017 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 46.4 $ 3.3 $ 17.9 $ — $ 67.6 Accounts receivable, net — 266.4 175.2 — 441.6 Other current assets 66.0 22.1 130.6 (40.5 ) 178.2 Total current assets 112.4 291.8 323.7 (40.5 ) 687.4 Property and equipment, net 87.7 977.3 417.3 — 1,482.3 Goodwill — 854.6 1,117.1 — 1,971.7 Intangible assets, net 11.6 107.5 286.0 — 405.1 Deferred income tax assets 106.5 57.7 — (72.6 ) 91.6 Other long-term assets 50.9 107.3 87.1 — 245.3 Intercompany notes receivable 503.4 — — (503.4 ) — Intercompany receivable and investments in consolidated affiliates 2,821.6 221.1 — (3,042.7 ) — Total assets $ 3,694.1 $ 2,617.3 $ 2,231.2 $ (3,659.2 ) $ 4,883.4 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 32.7 $ 7.2 $ 8.7 $ (17.5 ) $ 31.1 Accounts payable 11.2 46.2 24.4 — 81.8 Accrued expenses and other current liabilities 180.7 84.9 155.7 (23.0 ) 398.3 Total current liabilities 224.6 138.3 188.8 (40.5 ) 511.2 Long-term debt, net of current portion 2,301.7 244.2 45.4 — 2,591.3 Intercompany notes payable — — 503.4 (503.4 ) — Other long-term liabilities 31.4 17.0 210.4 (72.4 ) 186.4 Intercompany payable — — 135.8 (135.8 ) — 2,557.7 399.5 1,083.8 (752.1 ) 3,288.9 Commitments and contingencies Redeemable noncontrolling interests — — 221.3 — 221.3 Shareholders’ equity: HealthSouth shareholders’ equity 1,136.4 2,217.8 689.3 (2,907.1 ) 1,136.4 Noncontrolling interests — — 236.8 — 236.8 Total shareholders’ equity 1,136.4 2,217.8 926.1 (2,907.1 ) 1,373.2 Total liabilities and shareholders’ equity $ 3,694.1 $ 2,617.3 $ 2,231.2 $ (3,659.2 ) $ 4,883.4 As of December 31, 2016 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 20.6 $ 1.6 $ 18.3 $ — $ 40.5 Accounts receivable, net — 273.3 170.5 — 443.8 Other current assets 49.9 24.0 114.9 (18.6 ) 170.2 Total current assets 70.5 298.9 303.7 (18.6 ) 654.5 Property and equipment, net 41.6 979.7 370.5 — 1,391.8 Goodwill — 858.4 1,068.8 — 1,927.2 Intangible assets, net 12.0 115.5 283.8 — 411.3 Deferred income tax assets 90.9 57.6 — (72.7 ) 75.8 Other long-term assets 49.0 95.1 77.2 — 221.3 Intercompany notes receivable 528.8 — — (528.8 ) — Intercompany receivable and investments in consolidated affiliates 2,855.5 107.7 — (2,963.2 ) — Total assets $ 3,648.3 $ 2,512.9 $ 2,104.0 $ (3,583.3 ) $ 4,681.9 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 40.0 $ 6.4 $ 8.2 $ (17.5 ) $ 37.1 Accounts payable 7.0 37.2 24.1 — 68.3 Accrued expenses and other current liabilities 150.7 81.7 138.9 (1.1 ) 370.2 Total current liabilities 197.7 125.3 171.2 (18.6 ) 475.6 Long-term debt, net of current portion 2,679.2 248.9 51.2 — 2,979.3 Intercompany notes payable — — 528.8 (528.8 ) — Other long-term liabilities 35.5 15.2 181.6 (72.3 ) 160.0 Intercompany payable — — 167.6 (167.6 ) — 2,912.4 389.4 1,100.4 (787.3 ) 3,614.9 Commitments and contingencies Redeemable noncontrolling interests — — 138.3 — 138.3 Shareholders’ equity: HealthSouth shareholders’ equity 735.9 2,123.5 672.5 (2,796.0 ) 735.9 Noncontrolling interests — — 192.8 — 192.8 Total shareholders’ equity 735.9 2,123.5 865.3 (2,796.0 ) 928.7 Total liabilities and shareholders’ equity $ 3,648.3 $ 2,512.9 $ 2,104.0 $ (3,583.3 ) $ 4,681.9 Nine Months Ended September 30, 2017 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 47.0 $ 261.5 $ 197.3 $ — $ 505.8 Cash flows from investing activities: Purchases of property and equipment (23.5 ) (67.7 ) (64.5 ) — (155.7 ) Additions to capitalized software costs (12.1 ) (0.2 ) (2.3 ) — (14.6 ) Acquisitions of businesses, net of cash acquired (10.9 ) — (25.7 ) — (36.6 ) Net change in restricted cash — — (9.9 ) — (9.9 ) Proceeds from repayment of intercompany note receivable 33.0 — — (33.0 ) — Other, net (2.7 ) 11.7 (1.4 ) — 7.6 Net cash used in investing activities (16.2 ) (56.2 ) (103.8 ) (33.0 ) (209.2 ) Cash flows from financing activities: Principal payments on debt, including pre-payments (123.1 ) — (2.3 ) — (125.4 ) Principal payments on intercompany note payable — — (33.0 ) 33.0 — Borrowings on revolving credit facility 241.3 — — — 241.3 Payments on revolving credit facility (255.3 ) — — — (255.3 ) Repurchases of common stock, including fees and expenses (38.1 ) — — — (38.1 ) Dividends paid on common stock (67.0 ) — — — (67.0 ) Proceeds from exercising stock warrants 26.6 — — — 26.6 Distributions paid to noncontrolling interests of consolidated affiliates — — (38.3 ) — (38.3 ) Taxes paid on behalf of employees for shares withheld (19.5 ) — (0.3 ) — (19.8 ) Other, net (1.5 ) (5.0 ) 13.0 — 6.5 Change in intercompany advances 231.6 (198.6 ) (33.0 ) — — Net cash used in financing activities (5.0 ) (203.6 ) (93.9 ) 33.0 (269.5 ) Increase (decrease) in cash and cash equivalents 25.8 1.7 (0.4 ) — 27.1 Cash and cash equivalents at beginning of period 20.6 1.6 18.3 — 40.5 Cash and cash equivalents at end of period $ 46.4 $ 3.3 $ 17.9 $ — $ 67.6 Supplemental schedule of noncash financing activities: Conversion of convertible debt $ 319.4 $ — $ — $ — $ 319.4 Nine Months Ended September 30, 2016 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 88.6 $ 260.2 $ 150.6 $ — $ 499.4 Cash flows from investing activities: Purchases of property and equipment (9.2 ) (54.2 ) (50.5 ) — (113.9 ) Additions to capitalized software costs (15.9 ) (0.1 ) (1.5 ) — (17.5 ) Acquisitions of businesses, net of cash acquired — — (19.6 ) — (19.6 ) Net change in restricted cash — — (7.1 ) — (7.1 ) Funding of intercompany note receivable (11.5 ) — — 11.5 — Proceeds from repayment of intercompany note receivable 22.0 — — (22.0 ) — Other, net (3.3 ) 0.5 4.6 — 1.8 Net cash used in investing activities (17.9 ) (53.8 ) (74.1 ) (10.5 ) (156.3 ) Cash flows from financing activities: Principal payments on debt, including pre-payments (192.9 ) (1.3 ) (1.0 ) — (195.2 ) Principal borrowings on intercompany note receivable — — 11.5 (11.5 ) — Principal payments on intercompany note payable — — (22.0 ) 22.0 — Borrowings on revolving credit facility 260.0 — — — 260.0 Payments on revolving credit facility (240.0 ) — — — (240.0 ) Repurchases of common stock, including fees and expenses (24.1 ) — — — (24.1 ) Dividends paid on common stock (62.4 ) — — — (62.4 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (49.5 ) — (49.5 ) Taxes paid on behalf of employees for shares withheld (9.9 ) — — — (9.9 ) Other, net 3.3 (4.4 ) (6.1 ) — (7.2 ) Change in intercompany advances 210.2 (201.6 ) (8.6 ) — — Net cash used in financing activities (55.8 ) (207.3 ) (75.7 ) 10.5 (328.3 ) Increase (decrease) in cash and cash equivalents 14.9 (0.9 ) 0.8 — 14.8 Cash and cash equivalents at beginning of period 41.2 1.2 19.2 — 61.6 Cash and cash equivalents at end of period $ 56.1 $ 0.3 $ 20.0 $ — $ 76.4

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements — In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” and has subsequently issued supplemental and/or clarifying ASUs (collectively “ASC 606”). ASC 606 outlines a five-step framework that intends to clarify the principles for recognizing revenue and eliminate industry-specific guidance. In addition, ASC 606 revises current disclosure requirements in an effort to help financial statement users better understand the nature, amount, timing, and uncertainty of revenue that is recognized. ASC 606 will be effective for our annual reporting period beginning on January 1, 2018, including interim periods within that year. ASC 606 may be applied retrospectively to each period presented or on a modified retrospective basis with the cumulative effect recognized as of the date of adoption. We are currently assessing the impact this guidance may have on our consolidated financial statements by analyzing our current portfolio of third-party payor contracts, including a review of historical accounting policies and practices to identify potential differences in applying the new guidance. We are also evaluating the nature and amount of data available to us in assessing implementation of ASC 606. Under ASC 606, substantially all amounts that were previously presented as Provision for doubtful accounts will be considered an implicit price concession in determining Net operating revenues . Amounts considered to be doubtful accounts under ASC 606 will be presented as a component of Total operating expenses within the consolidated statements of operations. Except for the adjustments discussed above, we do not expect the adoption of ASC 606 to have a material impact on our consolidated financial statements. We expect to adopt ASC 606 retrospectively effective January 1, 2018. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Topic 825): Recognition and Measurement of Financial Assets and Financial Liabilities.” This standard revises the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value. This revised standard requires the change in fair value of many equity investments to be recognized in Net income . This revised standard requires a modified retrospective application with a cumulative effect adjustment recognized in retained earnings as of the date of adoption and is effective for our interim and annual periods beginning January 1, 2018. While we are currently assessing the impact this guidance may have on our consolidated financial statements, we expect to recognize mark-to-market gains and losses associated with our available-for-sale equity securities through Net income instead of Accumulated other comprehensive income . We continue to review the requirements of this revised standard, but do not expect the adoption of this guidance to have a material impact on our consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” in order to increase transparency and comparability by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new standard, lessees will recognize a right-of-use asset and a corresponding lease liability for all leases other than leases that meet the definition of a short-term lease. The liability will be equal to the present value of future minimum lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in an expense pattern similar to current capital leases. Classification will be based on criteria that are similar to those applied in current lease accounting. This standard will be effective for our annual reporting period beginning on January 1, 2019. Early adoption is permitted. In transition, we will be required to recognize and measure leases beginning in the earliest period presented using a modified retrospective approach; therefore, we anticipate restating our consolidated financial statements for the two fiscal years prior to the year of adoption. While we are currently assessing the impact this guidance may have on our consolidated financial statements, we expect that virtually all of our existing operating leases will be reflected as right-of-use assets and liabilities on our consolidated balance sheets under the new standard. We do not expect to early adopt this standard. See Note 6, Property and Equipment , to the consolidated financial statements accompanying the 2016 Form 10-K for disclosure related to our operating leases. In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting (Topic 718),” to simplify various aspects of share-based payment accounting and presentation. The new standard requires entities to record all of the tax effects related to share-based payments at settlement (or expiration) through the income statement. This change is required to be applied prospectively to all excess tax benefits and tax deficiencies resulting from settlements after the date of adoption of the ASU. The standard eliminates the requirement to delay recognition of a windfall tax benefit until it reduces current taxes payable. This change is required to be applied on a modified retrospective basis. In addition, all income tax-related cash flows resulting from share-based windfall tax benefits are required to be reported as operating activities on the statement of cash flows as opposed to the current presentation as an inflow from financing activities and an outflow from operating activities. Either prospective or retrospective transition of this provision is permitted. The standard also clarifies that all cash payments made to taxing authorities on the employees’ behalf for withheld shares should be presented as financing activities on the statement of cash flows on a retrospective basis. Finally, the standard allows entities to make an accounting policy election to either estimate forfeitures for each period or account for forfeitures as they occur. For HealthSouth, this guidance was effective for its annual reporting period beginning January 1, 2017, including interim periods within that reporting period. As a result of our adoption of this guidance effective January 1, 2017, we recorded $0.4 million and $9.0 million of tax benefits in excess of compensation cost (“windfalls”) to Provision for income tax expense in our condensed consolidating statement of operations for the three and nine months ended September 30, 2017 , respectively . In addition, we elected to retrospectively apply the guidance governing presentation of windfalls on the statement of cash flows, which resulted in a reclassification of windfalls of $17.3 million from Cash flows from financing activities to Cash flows from operating activities for the year ended December 31, 2016 within our 2016 Form 10-K . We also retrospectively applied the change to the presentation of cash payments made to taxing authorities on the employees’ behalf for withheld shares on our condensed consolidating statements of cash flows for the nine months ended September 30, 2016, which resulted in a reclassification of $9.9 million from Cash flows from operating activities to Cash flows from financing activities . We did not elect an accounting policy change to record forfeitures as they occur and thus will continue to estimate forfeitures at each period. Except for the adjustments discussed above, the adoption of this guidance did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326),” which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new guidance is effective for HealthSouth for the annual period beginning January 1, 2020, including interim periods within that reporting period. Early adoption is permitted for HealthSouth beginning January 1, 2019. We continue to review the requirements of this standard and any potential impact it may have on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments,” to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. In addition, the standard clarifies when cash receipts and cash payments have aspects of more than one class of cash flows and cannot be separated, classification will depend on the predominant source or use. The new guidance requires retrospective application and is effective for HealthSouth for the annual reporting period beginning January 1, 2018, including interim periods within that reporting period. Early adoption is permitted. While we continue to review the requirements of this standard and any potential impact it may have on our consolidated financial statements, the clarification that debt prepayment premiums should be classified as financing activities will result in an immaterial increase in certain prior period operating cash inflows and a corresponding increase in financing cash outflows. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230), Restricted Cash,” to clarify how entities should present restricted cash and restricted cash equivalents in the statement of cash flows. The new guidance requires amounts generally described as restricted cash and restricted cash equivalents be included with Cash and cash equivalents when reconciling the total beginning and ending amounts for the periods shown on the statement of cash flows. The new guidance requires retrospective application and is effective for our annual reporting period beginning January 1, 2018, including interim periods within that reporting period. Early adoption is permitted. We continue to review the requirements of this revised standard and any potential impact it may have on our consolidated financial statements. We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Concentration of Net Operating Revenues by Payor	We derived consolidated Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Medicare 75.7 % 74.8 % 75.3 % 75.0 % Medicare Advantage 8.4 % 7.9 % 8.7 % 7.9 % Managed care 9.4 % 10.1 % 9.6 % 9.9 % Medicaid 2.9 % 3.3 % 2.8 % 3.3 % Other third-party payors 1.3 % 1.5 % 1.3 % 1.4 % Workers’ compensation 0.7 % 0.8 % 0.7 % 0.8 % Patients 0.5 % 0.5 % 0.5 % 0.5 % Other income 1.1 % 1.1 % 1.1 % 1.2 % Total 100.0 % 100.0 % 100.0 % 100.0 % Inpatient Rehabilitation Revenues Our inpatient rehabilitation segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Medicare 73.3 % 73.3 % 73.1 % 73.3 % Medicare Advantage 8.1 % 7.6 % 8.4 % 7.7 % Managed care 10.7 % 11.4 % 11.0 % 11.3 % Medicaid 3.4 % 3.0 % 3.1 % 3.0 % Other third-party payors 1.6 % 1.8 % 1.6 % 1.7 % Workers’ compensation 0.9 % 1.0 % 0.9 % 1.0 % Patients 0.6 % 0.6 % 0.6 % 0.6 % Other income 1.4 % 1.3 % 1.3 % 1.4 % Total 100.0 % 100.0 % 100.0 % 100.0 % Home Health and Hospice Revenues Our home health and hospice segment derived its Net operating revenues from the following payor sources: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Medicare 85.2 % 81.8 % 84.7 % 82.4 % Medicare Advantage 9.6 % 8.8 % 10.0 % 8.9 % Managed care 3.9 % 4.5 % 3.8 % 3.7 % Medicaid 1.1 % 4.7 % 1.3 % 4.8 % Patients 0.1 % 0.1 % 0.1 % 0.1 % Other income 0.1 % 0.1 % 0.1 % 0.1 % Total 100.0 % 100.0 % 100.0 % 100.0 %

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date	The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions): Total current assets $ 0.1 Identifiable intangible asset: Noncompete agreements (useful lives of 5 years) 0.7 Trade name (useful life of 1 year) 0.1 Certificates of need (useful lives of 10 years) 0.7 Licenses (useful lives of 10 years) 3.8 Goodwill 20.5 Total assets acquired 25.9 Total liabilities assumed (0.2 ) Net assets acquired $ 25.7 The fair value of the assets acquired at the acquisition date were as follows (in millions): Property and equipment $ 0.1 Identifiable intangible assets: Noncompete agreements (useful lives of 2 to 3 years) 0.6 Trade name (useful life of 20 years) 0.5 Certificate of need (useful life of 20 years) 9.8 Goodwill 24.0 Total assets acquired $ 35.0
Schedule of Noncash or Part Noncash Acquisitions	Information regarding the net cash paid for the home health acquisitions during each period presented is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Fair value of assets acquired $ 2.7 $ 1.9 $ 5.4 $ 3.4 Goodwill 13.1 8.3 20.5 16.3 Fair value of liabilities assumed (0.1 ) — (0.2 ) (0.1 ) Net cash paid for acquisitions $ 15.7 $ 10.2 $ 25.7 $ 19.6 Information regarding the net cash paid for the inpatient rehabilitation acquisitions during each period presented is as follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Fair value of assets acquired $ 5.4 $ 1.4 $ 11.0 $ 6.7 Goodwill 9.0 7.6 24.0 9.4 Fair value of noncontrolling interest owned by joint venture partner (14.4 ) (9.0 ) (24.1 ) (16.1 ) Net cash paid for acquisition $ — $ — $ 10.9 $ —
Summary of Actual and Pro Forma Results of Operations for Acquisitions	The following table summarizes the results of operations of the above mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2016 (in millions): Net Operating Revenues Net Income Attributable to HealthSouth Acquired entities only: Actual from acquisition date to September 30, 2017 $ 17.5 $ (5.9 ) Combined entity: Supplemental pro forma from 07/01/2017-09/30/2017 996.1 65.9 Combined entity: Supplemental pro forma from 07/01/2016-09/30/2016 942.3 63.5 Combined entity: Supplemental pro forma from 01/01/2017-09/30/2017 2,975.9 198.4 Combined entity: Supplemental pro forma from 01/01/2016-09/30/2016 2,805.3 188.1

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of carrying amounts and classifications of VIE's assets and liabilities	The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our consolidated balance sheet, are as follows (in millions): September 30, 2017 December 31, 2016 Assets Current assets: Cash and cash equivalents $ 1.8 $ 1.6 Accounts receivable, net of allowance for doubtful accounts 30.0 30.8 Other current assets 5.6 5.8 Total current assets 37.4 38.2 Property and equipment, net 143.1 140.0 Goodwill 73.5 73.5 Intangible assets, net 7.6 9.6 Other long-term assets 1.1 1.0 Total assets $ 262.7 $ 262.3 Liabilities Current liabilities: Current portion of long-term debt $ 1.7 $ 1.5 Accounts payable 6.9 6.8 Accrued expenses and other current liabilities 16.6 12.2 Total current liabilities 25.2 20.5 Long-term debt, net of current portion 28.7 29.8 Total liabilities $ 53.9 $ 50.3

Investments in and Advances t25

Investments in and Advances to Nonconsolidated Affiliates (Tables)	9 Months Ended
	Sep. 30, 2017
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Schedule of Combined Results of Operations of Equity Method Affiliates	The following summarizes the combined results of operations of our equity method affiliates (on a 100% basis, in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net operating revenues $ 9.9 $ 11.3 $ 31.0 $ 33.4 Operating expenses (5.6 ) (6.0 ) (18.1 ) (18.1 ) Income from continuing operations, net of tax 4.3 5.2 12.9 15.2 Net income 4.3 5.2 12.9 15.2

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Outstanding Long-term Debt	Our long-term debt outstanding consists of the following (in millions): September 30, 2017 December 31, 2016 Credit Agreement— Advances under revolving credit facility $ 138.0 $ 152.0 Term loan facilities 298.3 421.2 Bonds payable— 5.125% Senior Notes due 2023 295.7 295.3 5.75% Senior Notes due 2024 1,193.7 1,193.2 5.75% Senior Notes due 2025 344.3 343.9 2.00% Convertible Senior Subordinated Notes due 2043 — 275.7 Other notes payable 80.1 55.8 Capital lease obligations 272.3 279.3 2,622.4 3,016.4 Less: Current portion (31.1 ) (37.1 ) Long-term debt, net of current portion $ 2,591.3 $ 2,979.3
Schedule of Debt Maturities	The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions): Face Amount Net Amount October 1 through December 31, 2017 $ 7.4 $ 7.4 2018 31.6 31.6 2019 31.7 31.6 2020 24.4 24.4 2021 25.8 25.8 2022 399.2 397.4 Thereafter 2,120.4 2,104.2 Total $ 2,640.5 $ 2,622.4

Redeemable Noncontrolling Int27

Redeemable Noncontrolling Interests (Tables)	9 Months Ended
	Sep. 30, 2017
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest	The following is a summary of the activity related to our Redeemable noncontrolling interests during the nine months ended September 30, 2017 and 2016 (in millions): Nine Months Ended September 30, 2017 2016 Balance at beginning of period $ 138.3 $ 121.1 Net income attributable to noncontrolling interests 9.9 11.2 Distributions declared (3.3 ) (6.4 ) Contribution to joint venture 2.3 — Change in fair value 74.1 (16.5 ) Balance at end of period $ 221.3 $ 109.4
Reconciliation of Noncontrolling Interests	The following table reconciles the net income attributable to nonredeemable Noncontrolling interests , as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests , as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016 (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net income attributable to nonredeemable noncontrolling interests $ 15.0 $ 12.7 $ 43.3 $ 42.5 Net income attributable to redeemable noncontrolling interests 4.2 3.7 9.9 11.2 Net income attributable to noncontrolling interests $ 19.2 $ 16.4 $ 53.2 $ 53.7

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis	Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): Fair Value Measurements at Reporting Date Using As of September 30, 2017 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Valuation Technique (1) Other current assets: Current portion of restricted marketable securities $ 18.5 $ — $ 18.5 $ — M Other long-term assets: Restricted marketable securities 41.4 — 41.4 — M Redeemable noncontrolling interests 221.3 — — 221.3 I As of December 31, 2016 Other current assets: Current portion of restricted marketable securities $ 24.2 $ — $ 24.2 $ — M Other long-term assets: Restricted marketable securities 33.5 — 33.5 — M Redeemable noncontrolling interests 138.3 — — 138.3 I (1) The three valuation techniques are: market approach (M), cost approach (C), and income approach (I).
Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments	The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions): As of September 30, 2017 As of December 31, 2016 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Long-term debt: Advances under revolving credit facility $ 138.0 $ 138.0 $ 152.0 $ 152.0 Term loan facilities 298.3 300.0 421.2 422.5 5.125% Senior Notes due 2023 295.7 310.0 295.3 297.8 5.75% Senior Notes due 2024 1,193.7 1,231.5 1,193.2 1,216.6 5.75% Senior Notes due 2025 344.3 365.8 343.9 349.6 2.00% Convertible Senior Subordinated Notes due 2043 — — 275.7 382.6 Other notes payable 80.1 80.1 55.8 55.8 Financial commitments: Letters of credit — 35.4 — 33.3

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending liability for unrecognized tax benefits is as follows (in millions): Gross Unrecognized Income Tax Benefits Balance at December 31, 2016 $ 2.8 Gross amount of decreases in unrecognized tax benefits related to prior periods (0.4 ) Decreases in unrecognized tax benefits relating to settlements with taxing authorities (2.1 ) Balance at September 30, 2017 $ 0.3

Earnings per Common Share (Tabl

Earnings per Common Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Common Share	The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic: Numerator: Income from continuing operations $ 85.2 $ 78.2 $ 249.1 $ 236.3 Less: Net income attributable to noncontrolling interests included in continuing operations (19.2 ) (16.4 ) (53.2 ) (53.7 ) Less: Income allocated to participating securities (0.2 ) (0.2 ) (0.6 ) (0.6 ) Income from continuing operations attributable to HealthSouth common shareholders 65.8 61.6 195.3 182.0 Loss from discontinued operations, net of tax, attributable to HealthSouth common shareholders (0.1 ) (0.1 ) (0.2 ) (0.3 ) Net income attributable to HealthSouth common shareholders $ 65.7 $ 61.5 $ 195.1 $ 181.7 Denominator: Basic weighted average common shares outstanding 97.8 89.1 92.3 89.3 Basic earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.67 $ 0.69 $ 2.11 $ 2.03 Discontinued operations — — — — Net income $ 0.67 $ 0.69 $ 2.11 $ 2.03 Diluted: Numerator: Income from continuing operations $ 85.2 $ 78.2 $ 249.1 $ 236.3 Less: Net income attributable to noncontrolling interests included in continuing operations (19.2 ) (16.4 ) (53.2 ) (53.7 ) Add: Interest on convertible debt, net of tax — 2.4 4.6 7.2 Add: Loss on extinguishment of convertible debt, net of tax — — 6.2 — Income from continuing operations attributable to HealthSouth common shareholders 66.0 64.2 206.7 189.8 Loss from discontinued operations, net of tax, attributable to HealthSouth common shareholders (0.1 ) (0.1 ) (0.2 ) (0.3 ) Net income attributable to HealthSouth common shareholders $ 65.9 $ 64.1 $ 206.5 $ 189.5 Denominator: Diluted weighted average common shares outstanding 99.0 99.4 99.1 99.5 Diluted earnings per share attributable to HealthSouth common shareholders: Continuing operations $ 0.67 $ 0.64 $ 2.08 $ 1.90 Discontinued operations — — — — Net income $ 0.67 $ 0.64 $ 2.08 $ 1.90
Reconciliation of Weighted Average Number of Shares Outstanding	The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Basic weighted average common shares outstanding 97.8 89.1 92.3 89.3 Convertible senior subordinated notes — 8.5 5.4 8.5 Restricted stock awards, dilutive stock options, and restricted stock units 1.2 1.8 1.4 1.7 Diluted weighted average common shares outstanding 99.0 99.4 99.1 99.5
Schedule of Warrants	The following table summarizes information relating to these warrants and their activity through their expiration date (number of warrants in millions): Number of Warrants Weighted-Average Exercise Price Common stock warrants outstanding as of December 31, 2016 8.2 $ 41.40 Cashless exercise (6.5 ) 41.40 Cash exercise (0.6 ) 41.40 Expired (1.1 ) 41.40 Common stock warrants outstanding as of January 17, 2017 —

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Selected financial information for our reportable segments is as follows (in millions): Inpatient Rehabilitation Home Health and Hospice Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 2017 2016 2017 2016 Net operating revenues $ 794.8 $ 751.7 $ 2,377.3 $ 2,253.5 $ 200.8 $ 175.1 $ 574.4 $ 503.8 Less: Provision for doubtful accounts (11.3 ) (13.7 ) (38.4 ) (43.8 ) (1.3 ) (1.1 ) (4.3 ) (2.9 ) Net operating revenues less provision for doubtful accounts 783.5 738.0 2,338.9 2,209.7 199.5 174.0 570.1 500.9 Operating expenses: Inpatient rehabilitation: Salaries and benefits 403.2 371.2 1,195.7 1,107.2 — — — — Other operating expenses 117.4 110.1 342.1 321.7 — — — — Supplies 33.1 31.9 100.6 96.1 — — — — Occupancy costs 15.7 15.0 46.3 46.0 — — — — Home health and hospice: Cost of services sold (excluding depreciation and amortization) — — — — 93.5 86.8 271.2 246.8 Support and overhead costs — — — — 68.9 59.5 203.4 174.5 569.4 528.2 1,684.7 1,571.0 162.4 146.3 474.6 421.3 Other income (1.0 ) (0.8 ) (2.9 ) (2.1 ) — — — — Equity in net income of nonconsolidated affiliates (1.9 ) (2.3 ) (5.6 ) (6.7 ) (0.2 ) (0.2 ) (0.6 ) (0.6 ) Noncontrolling interests 16.7 14.3 48.6 47.9 2.5 2.1 4.6 5.8 Segment Adjusted EBITDA $ 200.3 $ 198.6 $ 614.1 $ 599.6 $ 34.8 $ 25.8 $ 91.5 $ 74.4 Capital expenditures $ 59.1 $ 42.7 $ 164.7 $ 128.9 $ 1.7 $ 2.2 $ 5.6 $ 4.6
Reconciliation of Assets from Segment to Consolidated	September 30, 2017 December 31, 2016 Total assets for reportable segments $ 4,953.8 $ 4,753.3 Reclassification of deferred income tax liabilities to net deferred income tax assets (70.4 ) (71.4 ) Total consolidated assets $ 4,883.4 $ 4,681.9 Inpatient Rehabilitation Home Health and Hospice HealthSouth Consolidated As of September 30, 2017 Total assets $ 3,812.4 $ 1,141.4 $ 4,883.4 Investments in and advances to nonconsolidated affiliates 10.0 2.6 12.6 As of December 31, 2016 Total assets $ 3,629.6 $ 1,123.7 $ 4,681.9 Investments in and advances to nonconsolidated affiliates 10.6 2.4 13.0
Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense	Segment reconciliations (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total segment Adjusted EBITDA $ 235.1 $ 224.4 $ 705.6 $ 674.0 General and administrative expenses (39.7 ) (30.3 ) (128.6 ) (96.6 ) Depreciation and amortization (46.2 ) (43.5 ) (137.2 ) (128.8 ) Loss on disposal of assets (3.0 ) (1.6 ) (3.3 ) (2.0 ) Professional fees—accounting, tax, and legal — — — (1.9 ) Loss on early extinguishment of debt (0.3 ) (2.6 ) (10.7 ) (7.4 ) Interest expense and amortization of debt discounts and fees (36.8 ) (42.5 ) (118.5 ) (130.5 ) Net income attributable to noncontrolling interests 19.2 16.4 53.2 53.7 Income from continuing operations before income tax expense $ 128.3 $ 120.3 $ 360.5 $ 360.5
Reconciliation of Revenue from Segments to Consolidated	Additional detail regarding the revenues of our operating segments by service line follows (in millions): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Inpatient rehabilitation: Inpatient $ 768.6 $ 724.1 $ 2,297.7 $ 2,164.6 Outpatient and other 26.2 27.6 79.6 88.9 Total inpatient rehabilitation 794.8 751.7 2,377.3 2,253.5 Home health and hospice: Home health 181.2 162.0 519.4 470.0 Hospice 19.6 13.1 55.0 33.8 Total home health and hospice 200.8 175.1 574.4 503.8 Total net operating revenues $ 995.6 $ 926.8 $ 2,951.7 $ 2,757.3

Condensed Consolidating Finan32

Condensed Consolidating Financial Information (Tables)	9 Months Ended
	Sep. 30, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Statement of Operations	Three Months Ended September 30, 2017 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 5.3 $ 555.2 $ 466.5 $ (31.4 ) $ 995.6 Less: Provision for doubtful accounts — (7.7 ) (4.9 ) — (12.6 ) Net operating revenues less provision for doubtful accounts 5.3 547.5 461.6 (31.4 ) 983.0 Operating expenses: Salaries and benefits 9.1 266.4 271.9 (5.3 ) 542.1 Other operating expenses 8.0 83.6 58.2 (12.2 ) 137.6 Occupancy costs 0.4 23.4 8.7 (13.9 ) 18.6 Supplies — 22.4 14.1 — 36.5 General and administrative expenses 35.6 — 4.1 — 39.7 Depreciation and amortization 2.0 25.8 18.4 — 46.2 Total operating expenses 55.1 421.6 375.4 (31.4 ) 820.7 Loss on early extinguishment of debt 0.3 — — — 0.3 Interest expense and amortization of debt discounts and fees 30.8 5.3 6.3 (5.6 ) 36.8 Other income (5.7 ) (0.1 ) (0.8 ) 5.6 (1.0 ) Equity in net income of nonconsolidated affiliates — (1.9 ) (0.2 ) — (2.1 ) Equity in net income of consolidated affiliates (85.0 ) (11.8 ) — 96.8 — Management fees (35.8 ) 26.4 9.4 — — Income from continuing operations before income tax (benefit) expense 45.6 108.0 71.5 (96.8 ) 128.3 Provision for income tax (benefit) expense (20.4 ) 43.1 20.4 — 43.1 Income from continuing operations 66.0 64.9 51.1 (96.8 ) 85.2 Loss from discontinued operations, net of tax (0.1 ) — — — (0.1 ) Net income 65.9 64.9 51.1 (96.8 ) 85.1 Less: Net income attributable to noncontrolling interests — — (19.2 ) — (19.2 ) Net income attributable to HealthSouth $ 65.9 $ 64.9 $ 31.9 $ (96.8 ) $ 65.9 Comprehensive income $ 65.9 $ 64.9 $ 51.1 $ (96.8 ) $ 85.1 Comprehensive income attributable to HealthSouth $ 65.9 $ 64.9 $ 31.9 $ (96.8 ) $ 65.9 Three Months Ended September 30, 2016 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 4.9 $ 541.8 $ 409.8 $ (29.7 ) $ 926.8 Less: Provision for doubtful accounts — (10.0 ) (4.8 ) — (14.8 ) Net operating revenues less provision for doubtful accounts 4.9 531.8 405.0 (29.7 ) 912.0 Operating expenses: Salaries and benefits 10.4 250.2 241.4 (4.6 ) 497.4 Other operating expenses 6.4 79.4 52.3 (11.8 ) 126.3 Occupancy costs 0.6 22.4 7.9 (13.3 ) 17.6 Supplies — 22.4 12.4 — 34.8 General and administrative expenses 30.4 — (0.1 ) — 30.3 Depreciation and amortization 2.3 25.9 15.3 — 43.5 Total operating expenses 50.1 400.3 329.2 (29.7 ) 749.9 Loss on early extinguishment of debt 2.6 — — — 2.6 Interest expense and amortization of debt discounts and fees 36.3 5.4 5.8 (5.0 ) 42.5 Other income (5.1 ) (0.1 ) (0.6 ) 5.0 (0.8 ) Equity in net income of nonconsolidated affiliates — (2.3 ) (0.2 ) — (2.5 ) Equity in net income of consolidated affiliates (85.7 ) (9.8 ) — 95.5 — Management fees (33.9 ) 25.8 8.1 — — Income from continuing operations before income tax (benefit) expense 40.6 112.5 62.7 (95.5 ) 120.3 Provision for income tax (benefit) expense (21.2 ) 44.9 18.4 — 42.1 Income from continuing operations 61.8 67.6 44.3 (95.5 ) 78.2 Loss from discontinued operations, net of tax (0.1 ) — — — (0.1 ) Net income 61.7 67.6 44.3 (95.5 ) 78.1 Less: Net income attributable to noncontrolling interests — — (16.4 ) — (16.4 ) Net income attributable to HealthSouth $ 61.7 $ 67.6 $ 27.9 $ (95.5 ) $ 61.7 Comprehensive income $ 61.6 $ 67.6 $ 44.3 $ (95.5 ) $ 78.0 Comprehensive income attributable to HealthSouth $ 61.6 $ 67.6 $ 27.9 $ (95.5 ) $ 61.6 Nine Months Ended September 30, 2017 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 15.9 $ 1,693.9 $ 1,336.2 $ (94.3 ) $ 2,951.7 Less: Provision for doubtful accounts — (27.3 ) (15.4 ) — (42.7 ) Net operating revenues less provision for doubtful accounts 15.9 1,666.6 1,320.8 (94.3 ) 2,909.0 Operating expenses: Salaries and benefits 29.1 803.7 783.0 (15.8 ) 1,600.0 Other operating expenses 23.8 239.5 170.2 (36.3 ) 397.2 Occupancy costs 1.4 70.0 25.6 (42.2 ) 54.8 Supplies — 69.4 41.2 — 110.6 General and administrative expenses 104.7 — 23.9 — 128.6 Depreciation and amortization 6.7 77.3 53.2 — 137.2 Total operating expenses 165.7 1,259.9 1,097.1 (94.3 ) 2,428.4 Loss on early extinguishment of debt 10.7 — — — 10.7 Interest expense and amortization of debt discounts and fees 100.5 15.9 18.1 (16.0 ) 118.5 Other income (16.5 ) (0.2 ) (2.2 ) 16.0 (2.9 ) Equity in net income of nonconsolidated affiliates — (5.6 ) (0.6 ) — (6.2 ) Equity in net income of consolidated affiliates (256.4 ) (29.3 ) — 285.7 — Management fees (107.8 ) 80.7 27.1 — — Income from continuing operations before income tax (benefit) expense 119.7 345.2 181.3 (285.7 ) 360.5 Provision for income tax (benefit) expense (76.2 ) 137.7 49.9 — 111.4 Income from continuing operations 195.9 207.5 131.4 (285.7 ) 249.1 Loss from discontinued operations, net of tax (0.2 ) — — — (0.2 ) Net income 195.7 207.5 131.4 (285.7 ) 248.9 Less: Net income attributable to noncontrolling interests — — (53.2 ) — (53.2 ) Net income attributable to HealthSouth $ 195.7 $ 207.5 $ 78.2 $ (285.7 ) $ 195.7 Comprehensive income $ 196.0 $ 207.5 $ 131.4 $ (285.7 ) $ 249.2 Comprehensive income attributable to HealthSouth $ 196.0 $ 207.5 $ 78.2 $ (285.7 ) $ 196.0 Nine Months Ended September 30, 2016 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net operating revenues $ 14.9 $ 1,621.2 $ 1,209.2 $ (88.0 ) $ 2,757.3 Less: Provision for doubtful accounts — (32.1 ) (14.6 ) — (46.7 ) Net operating revenues less provision for doubtful accounts 14.9 1,589.1 1,194.6 (88.0 ) 2,710.6 Operating expenses: Salaries and benefits 32.7 746.4 704.2 (13.7 ) 1,469.6 Other operating expenses 18.9 230.1 152.4 (34.4 ) 367.0 Occupancy costs 2.4 67.2 23.8 (39.9 ) 53.5 Supplies — 67.1 37.1 — 104.2 General and administrative expenses 94.7 — 1.9 — 96.6 Depreciation and amortization 7.1 77.3 44.4 — 128.8 Professional fees—accounting, tax, and legal 1.9 — — — 1.9 Total operating expenses 157.7 1,188.1 963.8 (88.0 ) 2,221.6 Loss on early extinguishment of debt 7.4 — — — 7.4 Interest expense and amortization of debt discounts and fees 111.7 16.3 17.2 (14.7 ) 130.5 Other income (14.6 ) (0.2 ) (2.0 ) 14.7 (2.1 ) Equity in net income of nonconsolidated affiliates — (6.7 ) (0.6 ) — (7.3 ) Equity in net income of consolidated affiliates (259.7 ) (30.8 ) — 290.5 — Management fees (101.9 ) 77.0 24.9 — — Income from continuing operations before income tax (benefit) expense 114.3 345.4 191.3 (290.5 ) 360.5 Provision for income tax (benefit) expense (68.3 ) 137.8 54.7 — 124.2 Income from continuing operations 182.6 207.6 136.6 (290.5 ) 236.3 Loss from discontinued operations, net of tax (0.3 ) — — — (0.3 ) Net income 182.3 207.6 136.6 (290.5 ) 236.0 Less: Net income attributable to noncontrolling interests — — (53.7 ) — (53.7 ) Net income attributable to HealthSouth $ 182.3 $ 207.6 $ 82.9 $ (290.5 ) $ 182.3 Comprehensive income $ 182.5 $ 207.6 $ 136.6 $ (290.5 ) $ 236.2 Comprehensive income attributable to HealthSouth $ 182.5 $ 207.6 $ 82.9 $ (290.5 ) $ 182.5
Condensed Consolidating Balance Sheet	As of September 30, 2017 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 46.4 $ 3.3 $ 17.9 $ — $ 67.6 Accounts receivable, net — 266.4 175.2 — 441.6 Other current assets 66.0 22.1 130.6 (40.5 ) 178.2 Total current assets 112.4 291.8 323.7 (40.5 ) 687.4 Property and equipment, net 87.7 977.3 417.3 — 1,482.3 Goodwill — 854.6 1,117.1 — 1,971.7 Intangible assets, net 11.6 107.5 286.0 — 405.1 Deferred income tax assets 106.5 57.7 — (72.6 ) 91.6 Other long-term assets 50.9 107.3 87.1 — 245.3 Intercompany notes receivable 503.4 — — (503.4 ) — Intercompany receivable and investments in consolidated affiliates 2,821.6 221.1 — (3,042.7 ) — Total assets $ 3,694.1 $ 2,617.3 $ 2,231.2 $ (3,659.2 ) $ 4,883.4 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 32.7 $ 7.2 $ 8.7 $ (17.5 ) $ 31.1 Accounts payable 11.2 46.2 24.4 — 81.8 Accrued expenses and other current liabilities 180.7 84.9 155.7 (23.0 ) 398.3 Total current liabilities 224.6 138.3 188.8 (40.5 ) 511.2 Long-term debt, net of current portion 2,301.7 244.2 45.4 — 2,591.3 Intercompany notes payable — — 503.4 (503.4 ) — Other long-term liabilities 31.4 17.0 210.4 (72.4 ) 186.4 Intercompany payable — — 135.8 (135.8 ) — 2,557.7 399.5 1,083.8 (752.1 ) 3,288.9 Commitments and contingencies Redeemable noncontrolling interests — — 221.3 — 221.3 Shareholders’ equity: HealthSouth shareholders’ equity 1,136.4 2,217.8 689.3 (2,907.1 ) 1,136.4 Noncontrolling interests — — 236.8 — 236.8 Total shareholders’ equity 1,136.4 2,217.8 926.1 (2,907.1 ) 1,373.2 Total liabilities and shareholders’ equity $ 3,694.1 $ 2,617.3 $ 2,231.2 $ (3,659.2 ) $ 4,883.4 As of December 31, 2016 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Assets Current assets: Cash and cash equivalents $ 20.6 $ 1.6 $ 18.3 $ — $ 40.5 Accounts receivable, net — 273.3 170.5 — 443.8 Other current assets 49.9 24.0 114.9 (18.6 ) 170.2 Total current assets 70.5 298.9 303.7 (18.6 ) 654.5 Property and equipment, net 41.6 979.7 370.5 — 1,391.8 Goodwill — 858.4 1,068.8 — 1,927.2 Intangible assets, net 12.0 115.5 283.8 — 411.3 Deferred income tax assets 90.9 57.6 — (72.7 ) 75.8 Other long-term assets 49.0 95.1 77.2 — 221.3 Intercompany notes receivable 528.8 — — (528.8 ) — Intercompany receivable and investments in consolidated affiliates 2,855.5 107.7 — (2,963.2 ) — Total assets $ 3,648.3 $ 2,512.9 $ 2,104.0 $ (3,583.3 ) $ 4,681.9 Liabilities and Shareholders’ Equity Current liabilities: Current portion of long-term debt $ 40.0 $ 6.4 $ 8.2 $ (17.5 ) $ 37.1 Accounts payable 7.0 37.2 24.1 — 68.3 Accrued expenses and other current liabilities 150.7 81.7 138.9 (1.1 ) 370.2 Total current liabilities 197.7 125.3 171.2 (18.6 ) 475.6 Long-term debt, net of current portion 2,679.2 248.9 51.2 — 2,979.3 Intercompany notes payable — — 528.8 (528.8 ) — Other long-term liabilities 35.5 15.2 181.6 (72.3 ) 160.0 Intercompany payable — — 167.6 (167.6 ) — 2,912.4 389.4 1,100.4 (787.3 ) 3,614.9 Commitments and contingencies Redeemable noncontrolling interests — — 138.3 — 138.3 Shareholders’ equity: HealthSouth shareholders’ equity 735.9 2,123.5 672.5 (2,796.0 ) 735.9 Noncontrolling interests — — 192.8 — 192.8 Total shareholders’ equity 735.9 2,123.5 865.3 (2,796.0 ) 928.7 Total liabilities and shareholders’ equity $ 3,648.3 $ 2,512.9 $ 2,104.0 $ (3,583.3 ) $ 4,681.9
Condensed Consolidating Statement of Cash Flows	Nine Months Ended September 30, 2017 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 47.0 $ 261.5 $ 197.3 $ — $ 505.8 Cash flows from investing activities: Purchases of property and equipment (23.5 ) (67.7 ) (64.5 ) — (155.7 ) Additions to capitalized software costs (12.1 ) (0.2 ) (2.3 ) — (14.6 ) Acquisitions of businesses, net of cash acquired (10.9 ) — (25.7 ) — (36.6 ) Net change in restricted cash — — (9.9 ) — (9.9 ) Proceeds from repayment of intercompany note receivable 33.0 — — (33.0 ) — Other, net (2.7 ) 11.7 (1.4 ) — 7.6 Net cash used in investing activities (16.2 ) (56.2 ) (103.8 ) (33.0 ) (209.2 ) Cash flows from financing activities: Principal payments on debt, including pre-payments (123.1 ) — (2.3 ) — (125.4 ) Principal payments on intercompany note payable — — (33.0 ) 33.0 — Borrowings on revolving credit facility 241.3 — — — 241.3 Payments on revolving credit facility (255.3 ) — — — (255.3 ) Repurchases of common stock, including fees and expenses (38.1 ) — — — (38.1 ) Dividends paid on common stock (67.0 ) — — — (67.0 ) Proceeds from exercising stock warrants 26.6 — — — 26.6 Distributions paid to noncontrolling interests of consolidated affiliates — — (38.3 ) — (38.3 ) Taxes paid on behalf of employees for shares withheld (19.5 ) — (0.3 ) — (19.8 ) Other, net (1.5 ) (5.0 ) 13.0 — 6.5 Change in intercompany advances 231.6 (198.6 ) (33.0 ) — — Net cash used in financing activities (5.0 ) (203.6 ) (93.9 ) 33.0 (269.5 ) Increase (decrease) in cash and cash equivalents 25.8 1.7 (0.4 ) — 27.1 Cash and cash equivalents at beginning of period 20.6 1.6 18.3 — 40.5 Cash and cash equivalents at end of period $ 46.4 $ 3.3 $ 17.9 $ — $ 67.6 Supplemental schedule of noncash financing activities: Conversion of convertible debt $ 319.4 $ — $ — $ — $ 319.4 Nine Months Ended September 30, 2016 HealthSouth Corporation Guarantor Subsidiaries Nonguarantor Subsidiaries Eliminating Entries HealthSouth Consolidated (In Millions) Net cash provided by operating activities $ 88.6 $ 260.2 $ 150.6 $ — $ 499.4 Cash flows from investing activities: Purchases of property and equipment (9.2 ) (54.2 ) (50.5 ) — (113.9 ) Additions to capitalized software costs (15.9 ) (0.1 ) (1.5 ) — (17.5 ) Acquisitions of businesses, net of cash acquired — — (19.6 ) — (19.6 ) Net change in restricted cash — — (7.1 ) — (7.1 ) Funding of intercompany note receivable (11.5 ) — — 11.5 — Proceeds from repayment of intercompany note receivable 22.0 — — (22.0 ) — Other, net (3.3 ) 0.5 4.6 — 1.8 Net cash used in investing activities (17.9 ) (53.8 ) (74.1 ) (10.5 ) (156.3 ) Cash flows from financing activities: Principal payments on debt, including pre-payments (192.9 ) (1.3 ) (1.0 ) — (195.2 ) Principal borrowings on intercompany note receivable — — 11.5 (11.5 ) — Principal payments on intercompany note payable — — (22.0 ) 22.0 — Borrowings on revolving credit facility 260.0 — — — 260.0 Payments on revolving credit facility (240.0 ) — — — (240.0 ) Repurchases of common stock, including fees and expenses (24.1 ) — — — (24.1 ) Dividends paid on common stock (62.4 ) — — — (62.4 ) Distributions paid to noncontrolling interests of consolidated affiliates — — (49.5 ) — (49.5 ) Taxes paid on behalf of employees for shares withheld (9.9 ) — — — (9.9 ) Other, net 3.3 (4.4 ) (6.1 ) — (7.2 ) Change in intercompany advances 210.2 (201.6 ) (8.6 ) — — Net cash used in financing activities (55.8 ) (207.3 ) (75.7 ) 10.5 (328.3 ) Increase (decrease) in cash and cash equivalents 14.9 (0.9 ) 0.8 — 14.8 Cash and cash equivalents at beginning of period 41.2 1.2 19.2 — 61.6 Cash and cash equivalents at end of period $ 56.1 $ 0.3 $ 20.0 $ — $ 76.4

Basis of Presentation - Table 1

Basis of Presentation - Table 1 (Details) - state	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Concentration Risk [Line Items]
Number of states in which entity operates	36		36
Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Number of states in which entity operates	31		31
Home Health and Hospice Segment [Member]
Concentration Risk [Line Items]
Number of states in which entity operates	28		28
Net operating revenues [Member] | Payor Source [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	100.00%	100.00%	100.00%	100.00%
Net operating revenues [Member] | Payor Source [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	100.00%	100.00%	100.00%	100.00%
Net operating revenues [Member] | Payor Source [Member] | Home Health and Hospice Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	100.00%	100.00%	100.00%	100.00%
Net operating revenues [Member] | Payor Source [Member] | Other Income Source [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	1.10%	1.10%	1.10%	1.20%
Net operating revenues [Member] | Payor Source [Member] | Other Income Source [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	1.40%	1.30%	1.30%	1.40%
Net operating revenues [Member] | Payor Source [Member] | Other Income Source [Member] | Home Health and Hospice Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	0.10%	0.10%	0.10%	0.10%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicare [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	75.70%	74.80%	75.30%	75.00%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicare [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	73.30%	73.30%	73.10%	73.30%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicare [Member] | Home Health and Hospice Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	85.20%	81.80%	84.70%	82.40%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicare Advantage [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	8.40%	7.90%	8.70%	7.90%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicare Advantage [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	8.10%	7.60%	8.40%	7.70%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicare Advantage [Member] | Home Health and Hospice Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	9.60%	8.80%	10.00%	8.90%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Managed Care [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	9.40%	10.10%	9.60%	9.90%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Managed Care [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	10.70%	11.40%	11.00%	11.30%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Managed Care [Member] | Home Health and Hospice Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	3.90%	4.50%	3.80%	3.70%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicaid [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	2.90%	3.30%	2.80%	3.30%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicaid [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	3.40%	3.00%	3.10%	3.00%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Medicaid [Member] | Home Health and Hospice Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	1.10%	4.70%	1.30%	4.80%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Other Third-party Payors [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	1.30%	1.50%	1.30%	1.40%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Other Third-party Payors [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	1.60%	1.80%	1.60%	1.70%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Workers' Compensation [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	0.70%	0.80%	0.70%	0.80%
Net operating revenues [Member] | Payor Source [Member] | Third-Party Payor [Member] | Workers' Compensation [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	0.90%	1.00%	0.90%	1.00%
Net operating revenues [Member] | Payor Source [Member] | Self-Pay [Member] | Patients [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	0.50%	0.50%	0.50%	0.50%
Net operating revenues [Member] | Payor Source [Member] | Self-Pay [Member] | Patients [Member] | Inpatient Rehabilitation Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	0.60%	0.60%	0.60%	0.60%
Net operating revenues [Member] | Payor Source [Member] | Self-Pay [Member] | Patients [Member] | Home Health and Hospice Segment [Member]
Concentration Risk [Line Items]
Net operating revenues by payor source (percent)	0.10%	0.10%	0.10%	0.10%

Basis of Presentation Summary o

Basis of Presentation Summary of Significant Accounting Policies - Textual (Details) - Accounting Standards Update 2016-09 [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ 0.4	$ 9
Excess Tax Benefit from Share-based Compensation, Operating Activities				$ 17.3
Taxes paid on behalf of employees for shares withheld			$ 9.9

Business Combinations - Textual

Business Combinations - Textual (Details) $ in Millions	Sep. 01, 2017	Sep. 30, 2017USD ($)	Aug. 01, 2017location	Jul. 01, 2017location	May 01, 2017location	Apr. 08, 2017bed	Apr. 01, 2017bed	Feb. 01, 2017location
Inpatient Rehabilitation Segment [Member] | Memorial Hospital at Gulfport [Member]
Business Acquisition [Line Items]
Interest acquired in business acquisition (percent)							80.00%
Number of beds in facility acquired | bed							33
Inpatient Rehabilitation Segment [Member] | Mount Carmel West [Member]
Business Acquisition [Line Items]
Interest acquired in business acquisition (percent)						80.00%
Number of beds in facility acquired | bed						60
Inpatient Rehabilitation Segment [Member] | Jackson-Madison County General Hospital [Member]
Business Acquisition [Line Items]
Interest acquired in business acquisition (percent)				50.00%
Inpatient Rehabilitation Segment [Member] | Heritage Valley Beaver Hospital [Member]
Business Acquisition [Line Items]
Interest acquired in business acquisition (percent)	75.00%
Interest exchanged in business acquisition (percent)	25.00%
Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member]
Business Acquisition [Line Items]
Goodwill deductible for federal income tax purposes | $		$ 0
Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Acquired intangible asset useful lives		20 years
Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member] | Certificate of Need [Member]
Business Acquisition [Line Items]
Acquired intangible asset useful lives		20 years
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member]
Business Acquisition [Line Items]
Goodwill deductible for federal income tax purposes | $		$ 20.5
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Acquired intangible asset useful lives		5 years
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Acquired intangible asset useful lives		1 year
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member] | Certificate of Need [Member]
Business Acquisition [Line Items]
Acquired intangible asset useful lives		10 years
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member] | License [Member]
Business Acquisition [Line Items]
Acquired intangible asset useful lives		10 years
Home Health and Hospice Segment [Member] | Celtic Healthcare of Maryland, Inc. (Celtic) [Member]
Business Acquisition [Line Items]
Number of Locations of an Acquired Entity								2
Home health [Member] | Home Health and Hospice Segment [Member] | Community Health Services, Inc. (Community) [Member]
Business Acquisition [Line Items]
Number of Locations of an Acquired Entity								2
Home health [Member] | Home Health and Hospice Segment [Member] | Bio Care Home Health Services and Kinsman Enterprises [Member]
Business Acquisition [Line Items]
Number of Locations of an Acquired Entity					2
Home health [Member] | Home Health and Hospice Segment [Member] | VNA Healthtrends - IL, IN, AZ [Member]
Business Acquisition [Line Items]
Number of Locations of an Acquired Entity				4
Home health [Member] | Home Health and Hospice Segment [Member] | VNA Healthtrends - OH and IL [Member]
Business Acquisition [Line Items]
Number of Locations of an Acquired Entity			2
Minimum [Member] | Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Acquired intangible asset useful lives		2 years
Maximum [Member] | Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Acquired intangible asset useful lives		3 years

Business Combinations - Fair Va

Business Combinations - Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 1,971.7	$ 1,927.2
Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member]
Business Acquisition [Line Items]
Property and equipment	0.1
Goodwill	24
Total assets acquired	35
Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	0.6
Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	0.5
Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member] | Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	9.8
Home Health and Hospice Segment [Member]
Business Acquisition [Line Items]
Net assets acquired	25.7
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member]
Business Acquisition [Line Items]
Total current assets	0.1
Goodwill	20.5
Total assets acquired	25.9
Total liabilities assumed	0.2
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	0.7
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	0.1
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member] | Certificate of Need [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	0.7
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member] | License [Member]
Business Acquisition [Line Items]
Identifiable intangible assets	$ 3.8

Business Combinations - Net Cas

Business Combinations - Net Cash Paid for Acquisitions (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Net cash paid for acquisition			$ 36.6	$ 19.6
Home Health and Hospice Segment [Member] | Celtic, Community, Bio Care, and VNA [Member]
Business Acquisition [Line Items]
Fair value of assets acquired	$ 2.7	$ 1.9	5.4	3.4
Goodwill	13.1	8.3	20.5	16.3
Fair value of liabilities assumed	(0.1)	0	(0.2)	(0.1)
Net cash paid for acquisition	15.7	10.2	25.7	19.6
Inpatient Rehabilitation Segment [Member] | Gulfport, Mount Carmel, Jackson and Heritage Valley [Member]
Business Acquisition [Line Items]
Fair value of assets acquired	5.4	1.4	11	6.7
Goodwill	9	7.6	24	9.4
Far value of noncontrolling interest owned by joint venture partner	(14.4)	(9)	(24.1)	(16.1)
Net cash paid for acquisition	$ 0	$ 0	$ 10.9	$ 0

Business Combinations - Pro For

Business Combinations - Pro Forma Results of Operation (Details) - USD ($) $ in Millions	3 Months Ended		8 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Business Combinations [Abstract]
Acquired entity only: Actual from acquisition date to September 30, 2017, Net Operating Revenues			$ 17.5
Acquired entities only: Actual from acquisition date to September 30, 2017, Net Income Attributable to HealthSouth			$ (5.9)
Combined entity: Supplemental pro forma, Net Operating Revenues	$ 996.1	$ 942.3		$ 2,975.9	$ 2,805.3
Combined entity: Supplemental pro forma, Net Income Attributable to HealthSouth	$ 65.9	$ 63.5		$ 198.4	$ 188.1

Variable Interest Entities - Te

Variable Interest Entities - Textual (Details) - Consolidated Limited Partnership-like Entities [Member] - entity	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Variable Interest Entity [Line Items]
Number of consolidated limited partnership-like entities	10	10
Minimum [Member]
Variable Interest Entity [Line Items]
Ownership interest in consolidated entities (percent)	6.80%
Maximum [Member]
Variable Interest Entity [Line Items]
Ownership interest in consolidated entities (percent)	99.50%

Variable Interest Entities - Ta

Variable Interest Entities - Table 1 (Details) - USD ($) $ in Millions	Sep. 30, 2017		Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 67.6		$ 40.5	$ 76.4	$ 61.6
Accounts receivable, net of allowance for doubtful accounts	441.6		443.8
Other current assets	178.2		170.2
Total current assets	687.4		654.5
Property and equipment, net	1,482.3		1,391.8
Goodwill	1,971.7		1,927.2
Intangible assets, net	405.1		411.3
Other long-term assets	245.3		221.3
Total assets	4,883.4	[1]	4,681.9
Current portion of long-term debt	31.1		37.1
Accounts payable	81.8		68.3
Total current liabilities	511.2		475.6
Long-term debt, net of current portion	2,591.3		2,979.3
Total Liabilities	3,288.9		3,614.9
Consolidated VIEs [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	1.8		1.6
Accounts receivable, net of allowance for doubtful accounts	30		30.8
Other current assets	5.6		5.8
Total current assets	37.4		38.2
Property and equipment, net	143.1		140
Goodwill	73.5		73.5
Intangible assets, net	7.6		9.6
Other long-term assets	1.1		1
Total assets	262.7		262.3
Current portion of long-term debt	1.7		1.5
Accounts payable	6.9		6.8
Accrued expenses and other current liabilities	16.6		12.2
Total current liabilities	25.2		20.5
Long-term debt, net of current portion	28.7		29.8
Total Liabilities	$ 53.9		$ 50.3
[1]	Our consolidated assets as of September 30, 2017 and December 31, 2016 include total assets of variable interest entities of $262.7 million and $262.3 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2017 and December 31, 2016 include total liabilities of the variable interest entities of $53.9 million and $50.3 million, respectively. See Note 3, Variable Interest Entities.

Investments in and Advances t41

Investments in and Advances to Nonconsolidated Affiliates - Textual (Details) $ in Millions	Sep. 30, 2017USD ($)entity	Dec. 31, 2016USD ($)
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Investments in and advances to nonconsolidated affiliates | $	$ 12.6	$ 13
Number of partially owned subsidiaries	7
Number of partially owned general or limited partnerships, limited liability companies of joint ventures	6
Minimum [Member]
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Ownership interest in affiliates (percent)	1.00%
Maximum [Member]
Investments In and Advances to Nonconsolidated Affiliates (Textual) [Abstract]
Ownership interest in affiliates (percent)	60.00%

Investments In and Advances t42

Investments In and Advances to Nonconsolidated Affiliates - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Net operating revenues	$ 9.9	$ 11.3	$ 31	$ 33.4
Operating expenses	(5.6)	(6)	(18.1)	(18.1)
Income from continuing operations, net of tax	4.3	5.2	12.9	15.2
Net income	$ 4.3	$ 5.2	$ 12.9	$ 15.2

Long-term Debt - Table 1 (Detai

Long-term Debt - Table 1 (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Schedule of Outstanding Long-term Debt
Capital lease obligations	$ 272.3	$ 279.3
Total debt and capital lease obligations	2,622.4	3,016.4
Less: Current portion	(31.1)	(37.1)
Long-term debt, net of current portion	2,591.3	2,979.3
Term Loan Facilities [Member] | Term Loan Facilities [Member]
Schedule of Outstanding Long-term Debt
Total debt	$ 298.3	421.2
Senior Notes [Member] | 5.125% Senior Notes Due 2023 [Member]
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	5.125%
Total debt	$ 295.7	295.3
Senior Notes [Member] | 5.75% Senior Notes Due 2024 [Member]
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	5.75%
Total debt	$ 1,193.7	1,193.2
Senior Notes [Member] | 5.75% Senior Notes Due 2025 [Member]
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	5.75%
Total debt	$ 344.3	343.9
Senior Subordinated Notes [Member] | 2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Schedule of Outstanding Long-term Debt
Debt instrument interest rate (percent)	2.00%
Total debt	$ 0	275.7
Other Notes Payable [Member]
Schedule of Outstanding Long-term Debt
Total debt	80.1	55.8
Revolving Credit Facility [Member]
Schedule of Outstanding Long-term Debt
Total debt	$ 138	$ 152

Long-term Debt - Table 2 (Detai

Long-term Debt - Table 2 (Details) $ in Millions	Sep. 30, 2017USD ($)
Face Amount [Member]
Long-term Debt by Maturity
October 1 through December 31, 2017	$ 7.4
2,018	31.6
2,019	31.7
2,020	24.4
2,021	25.8
2,022	399.2
Thereafter	2,120.4
Total debt and capital lease obligations	2,640.5
Net Amount [Member]
Long-term Debt by Maturity
October 1 through December 31, 2017	7.4
2,018	31.6
2,019	31.6
2,020	24.4
2,021	25.8
2,022	397.4
Thereafter	2,104.2
Total debt and capital lease obligations	$ 2,622.4

Long-term Debt - Textual (Detai

Long-term Debt - Textual (Details) shares in Millions, $ in Millions	Sep. 29, 2017USD ($)	May 31, 2017USD ($)shares	Feb. 29, 2016	Sep. 30, 2017USD ($)shares	Jun. 30, 2017USD ($)	Mar. 31, 2017shares	Sep. 30, 2016USD ($)shares	Sep. 30, 2017USD ($)shares	Sep. 30, 2016USD ($)shares	Dec. 31, 2016USD ($)	Feb. 25, 2016renewal_option
Debt Instrument [Line Items]
Decrease in spread used to calculate interest rate	0.25%
Senior secured leverage ratio maximum				2				2
Debt Instrument, Convertible, Terms of Conversion Feature		27.2221 shares per $1,000 principal amount
Conversion of convertible debt		$ 319.4						$ 319.4	$ 0
Conversion of convertible debt, net of tax (shares) | shares		8.9
Stock Issued During Period, Shares, Conversion of Convertible Securities Due to Make-Whole Premium | shares		0.2
Convertible senior subordinated notes (shares) | shares				0		8.6	8.5	5.4	8.5
Repayments of Debt		$ 0.6
Loss on early extinguishment of debt				$ 0.3	$ 10.4		$ 2.6	$ 10.7	$ 7.4
Maximum permitted capital expenditures	$ 350									$ 300
Maximum leverage ratio	4.50									4.25
Maximum contractual future increase				870				870		$ 300
Noncurrent financing obligation liability				272.3				272.3		279.3
Development / Lease Agreement [Member]
Debt Instrument [Line Items]
Initial lease term			15 years
Number of renewal options | renewal_option											4
Renewal term			5 years
Increase in property plant and equipment, net								46.8		$ 20.3
Development / Lease Agreement [Member] | Financing Obligation [Member]
Debt Instrument [Line Items]
Total estimated financing obligation				56				56
Term Loan Facilities [Member]
Debt Instrument [Line Items]
Senior secured leverage ratio maximum	2									1.75
Other Notes Payable [Member] | Development / Lease Agreement [Member]
Debt Instrument [Line Items]
Noncurrent financing obligation liability				46.6				46.6		$ 20.3
Capital Lease Obligations, Current				$ 0.2				$ 0.2
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 700									$ 600
Term Loan Facilities [Member] | Term Loan Facilities [Member]
Debt Instrument [Line Items]
Repayments of Debt	110
Maximum borrowing capacity	$ 300

Redeemable Noncontrolling Int46

Redeemable Noncontrolling Interests - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period			$ 138.3
Net income attributable to noncontrolling interests	$ 4.2	$ 3.7	9.9	$ 11.2
Distributions declared			(37.1)	(43.1)
Change in fair value			(44.4)	10.2
Balance at end of period	221.3		221.3
Redeemable Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Balance at beginning of period			138.3	121.1
Net income attributable to noncontrolling interests			9.9	11.2
Distributions declared			(3.3)	(6.4)
Contribution to joint venture			2.3	0
Change in fair value			74.1	(16.5)
Balance at end of period	$ 221.3	$ 109.4	$ 221.3	$ 109.4

Redeemable Noncontrolling Int47

Redeemable Noncontrolling Interests - Table 2 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Noncontrolling Interest [Abstract]
Net income attributable to nonredeemable noncontrolling interests	$ 15	$ 12.7	$ 43.3	$ 42.5
Net income attributable to redeemable noncontrolling interests	4.2	3.7	9.9	11.2
Net income attributable to noncontrolling interests	$ 19.2	$ 16.4	$ 53.2	$ 53.7

Fair Value Measurements - Table

Fair Value Measurements - Table 1 (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Market Approach Valuation Technique [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Current portion of restricted marketable securities	$ 18.5	$ 24.2
Noncurrent portion of restricted marketable securities	41.4	33.5
Market Approach Valuation Technique [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Current portion of restricted marketable securities	0	0
Noncurrent portion of restricted marketable securities	0	0
Market Approach Valuation Technique [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Current portion of restricted marketable securities	18.5	24.2
Noncurrent portion of restricted marketable securities	41.4	33.5
Market Approach Valuation Technique [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Current portion of restricted marketable securities	0	0
Noncurrent portion of restricted marketable securities	0	0
Income Approach Valuation Technique [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable noncontrolling interests	221.3	138.3
Income Approach Valuation Technique [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable noncontrolling interests	0	0
Income Approach Valuation Technique [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable noncontrolling interests	0	0
Income Approach Valuation Technique [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]
Redeemable noncontrolling interests	$ 221.3	$ 138.3

Fair Value Measurements - Textu

Fair Value Measurements - Textuals (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gains or losses related to non-financial assets and liabilities	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements - Tab50

Fair Value Measurements - Table 2 (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Revolving Credit Facility [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 138	$ 152
Revolving Credit Facility [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	138	152
Letters of Credit [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	0	0
Letters of Credit [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	35.4	33.3
Term Loan Facilities [Member] | Term Loan Facilities [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	298.3	421.2
Term Loan Facilities [Member] | Term Loan Facilities [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 300	422.5
Senior Notes [Member] | 5.125% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	5.125%
Senior Notes [Member] | 5.125% Senior Notes Due 2023 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 295.7	295.3
Senior Notes [Member] | 5.125% Senior Notes Due 2023 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 310	297.8
Senior Notes [Member] | 5.75% Senior Notes Due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	5.75%
Senior Notes [Member] | 5.75% Senior Notes Due 2024 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 1,193.7	1,193.2
Senior Notes [Member] | 5.75% Senior Notes Due 2024 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 1,231.5	1,216.6
Senior Notes [Member] | 5.75% Senior Notes Due 2025 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	5.75%
Senior Notes [Member] | 5.75% Senior Notes Due 2025 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 344.3	343.9
Senior Notes [Member] | 5.75% Senior Notes Due 2025 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 365.8	349.6
Senior Subordinated Notes [Member] | 2.00% Convertible Senior Subordinated Notes due 2043 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument interest rate (percent)	2.00%
Senior Subordinated Notes [Member] | 2.00% Convertible Senior Subordinated Notes due 2043 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 0	275.7
Senior Subordinated Notes [Member] | 2.00% Convertible Senior Subordinated Notes due 2043 [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	0	382.6
Other Notes Payable [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	80.1	55.8
Other Notes Payable [Member] | Estimated Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying amounts and estimated fair values of financial instruments	$ 80.1	$ 55.8

Share-Based Payments Textual (D

Share-Based Payments Textual (Details) shares in Millions	4 Months Ended
	May 31, 2017shares
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards issued (shares)	0.6
Restricted Stock [Member] | Service Condition [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards issued (shares)	0.2
Restricted Stock [Member] | Service and Performance Condition [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance measurement period	2 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (shares)	0.1

Income Taxes - Textual (Details

Income Taxes - Textual (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2016
Income Tax Contingency [Line Items]
Provision for income tax expense	$ 43.1	$ 42.1	$ 111.4	$ 124.2
Net deferred tax assets	91.6		91.6
Valuation allowance	28.4		28.4
Additional tax benefits due to approval of accounting method change			55		$ 39
Gross unrecognized tax benefits	0.3		0.3			$ 2.8
Gross unrecognized tax benefits that would impact effective tax rate if recognized	0.3		0.3			$ 2.8
State and Local Jurisdiction [Member]
Income Tax Contingency [Line Items]
Operating Loss Carryforwards	$ 62		$ 62

Income Taxes - Table (Details)

Income Taxes - Table (Details) $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at December 31, 2016	$ 2.8
Gross amount of decreases in unrecognized tax benefits related to prior periods	(0.4)
Decreases in unrecognized tax benefits relating to settlements with taxing authorities	(2.1)
Balance at September 30, 2017	$ 0.3

Earnings per Common Share - Tab

Earnings per Common Share - Table 1 (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Basic Numerator:
Income from continuing operations	$ 85.2	$ 78.2	$ 249.1	$ 236.3
Less: Net income attributable to noncontrolling interests included in continuing operations	(19.2)	(16.4)	(53.2)	(53.7)
Less: Income allocated to participating securities	(0.2)	(0.2)	(0.6)	(0.6)
Income from continuing operations attributable to HealthSouth common shareholders	65.8	61.6	195.3	182
Loss from discontinued operations, net of tax	(0.1)	(0.1)	(0.2)	(0.3)
Net income attributable to HealthSouth common shareholders	$ 65.7	$ 61.5	$ 195.1	$ 181.7
Basic Denominator:
Basic weighted average common shares outstanding (shares)	97.8	89.1	92.3	89.3
Basic earnings per share attributable to HealthSouth common shareholders:
Continuing operations (in dollars per share)	$ 0.67	$ 0.69	$ 2.11	$ 2.03
Discontinued operations (in dollars per share)	0	0	0	0
Net Income (in dollars per share)	$ 0.67	$ 0.69	$ 2.11	$ 2.03
Diluted Numerator
Income from continuing operations	$ 85.2	$ 78.2	$ 249.1	$ 236.3
Less: Net income attributable to noncontrolling interests included in continuing operations	(19.2)	(16.4)	(53.2)	(53.7)
Add: Interest on convertible debt, net of tax	0	2.4	4.6	7.2
Add: Loss on extinguishment of convertible debt, net of tax	0	0	6.2	0
Income from continuing operations attributable to HealthSouth common shareholders	66	64.2	206.7	189.8
Loss from discontinued operations, net of tax	(0.1)	(0.1)	(0.2)	(0.3)
Net income attributable to HealthSouth common shareholders	$ 65.9	$ 64.1	$ 206.5	$ 189.5
Diluted Denominator
Diluted weighted average common shares outstanding (shares)	99	99.4	99.1	99.5
Diluted earnings per share attributable to HealthSouth common shareholders:
Continuing operations (in dollars per share)	$ 0.67	$ 0.64	$ 2.08	$ 1.90
Discontinued operations (in dollars per share)	0	0	0	0
Net income (in dollars per share)	$ 0.67	$ 0.64	$ 2.08	$ 1.90

Earnings per Common Share - T55

Earnings per Common Share - Table 2 (Details) - shares shares in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Basic weighted average common shares outstanding (shares)	97.8		89.1	92.3	89.3
Convertible senior subordinated notes (shares)	0	8.6	8.5	5.4	8.5
Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants (shares)	1.2		1.8	1.4	1.7
Diluted weighted average common shares outstanding (shares)	99		99.4	99.1	99.5

Earnings per Common Share - Tex

Earnings per Common Share - Textual (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Oct. 20, 2017	Oct. 16, 2017	Jul. 20, 2017	Oct. 20, 2016	Sep. 30, 2009	Jul. 31, 2017	May 31, 2017	Apr. 30, 2017	Feb. 28, 2017	Jan. 31, 2017	Jan. 17, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Cash dividends per common share, Declared (in dollars per share)			$ 0.25	$ 0.24								$ 0.25	$ 0.24	$ 0.73	$ 0.70
Stock warrants exercised (shares)					5						0.7
Class of Warrant or Right, Outstanding					8.2						0					8.2
Exercise price of warrants (in dollars per share)					$ 41.40						$ 41.40					$ 41.40
Proceeds from exercising stock warrants											$ 27			$ 26.6	$ 0
Common Stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Cash dividends per common share, Declared (in dollars per share)							$ 0.24		$ 0.24
Cash dividends per common share, Paid (in dollars per share)						$ 0.24		$ 0.24		$ 0.24
Common stock dividends accrued												$ 25.3		$ 25.3		$ 22.2
Subsequent Event [Member] | Common Stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Cash dividends per common share, Declared (in dollars per share)	$ 0.25
Cash dividends per common share, Paid (in dollars per share)		$ 0.25

Earnings per Common Share Earni

Earnings per Common Share Earnings per Common Share - Schedule of Warrant Activity (Details) - $ / shares shares in Millions	1 Months Ended
	Jan. 17, 2017	Dec. 31, 2016	Sep. 30, 2009
Class of Warrant or Right [Line Items]
Common stock warrants outstanding as of December 31, 2016	8.2
Expired	(1.1)
Common stock warrants outstanding as of January 17, 2017	0
Weighted average exercise price (in dollars per share)	$ 41.40	$ 41.40	$ 41.40
Cashless exercise [Member]
Class of Warrant or Right [Line Items]
Exercised	(6.5)
Weighted average exercise price (in dollars per share)	$ 41.40
Cash exercise [Member]
Class of Warrant or Right [Line Items]
Exercised	(0.6)
Weighted average exercise price (in dollars per share)	$ 41.40

Contingencies and Other Commi58

Contingencies and Other Commitments (Details) - Pending Litigation [Member] $ in Millions	May 18, 2016USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Feb. 28, 2015patient	Apr. 24, 2014facilities	Aug. 12, 2013facilities	Mar. 04, 2013facilitiespatient
Honts lawsuit [Member]
Loss Contingencies [Line Items]
Number of hospitals involved in lawsuit | facilities						1
Punitive damages awarded in favor of plaintiff	$ 20
Other operating expenses			$ 5.7
Loss contingency accrual		$ 20.2
Loss contingency receivable accrued		15.5
Portion of liability that would be covered through captive insurance subsidiary		$ 6
HHS-OIG Investigation [Member]
Loss Contingencies [Line Items]
Number of hospitals that received subpoenas | facilities					7		4
Number of patient medical records requested for each hospital in subpoenas | patient							100
Number of hospitals that received supplemental subpoenas | facilities					2
Number of additional patient medical records requested | patient				70
Compliance threshold under Health Care Act (percent)		60.00%

Segment Reporting - Textuals (D

Segment Reporting - Textuals (Details)	9 Months Ended
	Sep. 30, 2017locationstatefacilitiessegment
Segment Reporting Information [Line Items]
Number of operating segments | segment	2
Number of states in which entity operates | state	36
Inpatient Rehabilitation Segment [Member]
Segment Reporting Information [Line Items]
Number of states in which entity operates | state	31
Number of inpatient rehabilitation hospitals operated	126
Number of hospitals or agencies operated as a joint venture	1
Number of inpatient rehabilitation units under management contracts	4
Home Health and Hospice Segment [Member]
Segment Reporting Information [Line Items]
Number of states in which entity operates | state	28
Number of hospitals or agencies operated as a joint venture	2
Number of locations across the states | location	235

Segment Reporting - Table 1 (De

Segment Reporting - Table 1 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Net operating revenues	$ 995.6	$ 926.8	$ 2,951.7	$ 2,757.3
Less: Provision for doubtful accounts			(42.7)	(46.7)
Net operating revenues less provision for doubtful accounts	983	912	2,909	2,710.6
Costs and Expenses [Abstract]
Salaries and benefits	542.1	497.4	1,600	1,469.6
Other operating expenses	137.6	126.3	397.2	367
Supplies	36.5	34.8	110.6	104.2
Occupancy costs	18.6	17.6	54.8	53.5
Total operating expenses	820.7	749.9	2,428.4	2,221.6
Other income	(1)	(0.8)	(2.9)	(2.1)
Equity in net income of nonconsolidated affiliates	(2.1)	(2.5)	(6.2)	(7.3)
Net income attributable to noncontrolling interests	19.2	16.4	53.2	53.7
Inpatient Rehabilitation Segment [Member]
Segment Reporting Information [Line Items]
Net operating revenues	794.8	751.7	2,377.3	2,253.5
Less: Provision for doubtful accounts	(11.3)	(13.7)	(38.4)	(43.8)
Net operating revenues less provision for doubtful accounts	783.5	738	2,338.9	2,209.7
Costs and Expenses [Abstract]
Salaries and benefits	403.2	371.2	1,195.7	1,107.2
Other operating expenses	117.4	110.1	342.1	321.7
Supplies	33.1	31.9	100.6	96.1
Occupancy costs	15.7	15	46.3	46
Total operating expenses	569.4	528.2	1,684.7	1,571
Other income	(1)	(0.8)	(2.9)	(2.1)
Equity in net income of nonconsolidated affiliates	(1.9)	(2.3)	(5.6)	(6.7)
Net income attributable to noncontrolling interests	16.7	14.3	48.6	47.9
Segment Adjusted EBITDA	200.3	198.6	614.1	599.6
Capital Expenditures	59.1	42.7	164.7	128.9
Home Health and Hospice Segment [Member]
Segment Reporting Information [Line Items]
Net operating revenues	200.8	175.1	574.4	503.8
Less: Provision for doubtful accounts	(1.3)	(1.1)	(4.3)	(2.9)
Net operating revenues less provision for doubtful accounts	199.5	174	570.1	500.9
Costs and Expenses [Abstract]
Cost of services sold (excluding depreciation and amortization)	93.5	86.8	271.2	246.8
Support and overhead costs	68.9	59.5	203.4	174.5
Total operating expenses	162.4	146.3	474.6	421.3
Other income	0	0	0	0
Equity in net income of nonconsolidated affiliates	(0.2)	(0.2)	(0.6)	(0.6)
Net income attributable to noncontrolling interests	2.5	2.1	4.6	5.8
Segment Adjusted EBITDA	34.8	25.8	91.5	74.4
Capital Expenditures	$ 1.7	$ 2.2	$ 5.6	$ 4.6

Segment Reporting - Table 2 (De

Segment Reporting - Table 2 (Details) - USD ($) $ in Millions	Sep. 30, 2017		Dec. 31, 2016
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 4,883.4	[1]	$ 4,681.9
Investments in and advances to nonconsolidated affiliates	12.6		13
Inpatient Rehabilitation Segment [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	3,812.4		3,629.6
Investments in and advances to nonconsolidated affiliates	10		10.6
Home Health and Hospice Segment [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,141.4		1,123.7
Investments in and advances to nonconsolidated affiliates	$ 2.6		$ 2.4
[1]	Our consolidated assets as of September 30, 2017 and December 31, 2016 include total assets of variable interest entities of $262.7 million and $262.3 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2017 and December 31, 2016 include total liabilities of the variable interest entities of $53.9 million and $50.3 million, respectively. See Note 3, Variable Interest Entities.

Segment Reporting - Table 3 (De

Segment Reporting - Table 3 (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
General and administrative expenses	$ (39.7)		$ (30.3)	$ (128.6)	$ (96.6)
Depreciation and amortization	(46.2)		(43.5)	(137.2)	(128.8)
Professional fees—accounting, tax, and legal	0		0	0	(1.9)
Loss on early extinguishment of debt	(0.3)	$ (10.4)	(2.6)	(10.7)	(7.4)
Net income attributable to noncontrolling interests	19.2		16.4	53.2	53.7
Income from continuing operations before income tax expense	128.3		120.3	360.5	360.5
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total segment Adjusted EBITDA	235.1		224.4	705.6	674
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
General and administrative expenses	39.7		30.3	128.6	96.6
Depreciation and amortization	46.2		43.5	137.2	128.8
Loss on disposal of assets	(3)		(1.6)	(3.3)	(2)
Professional fees—accounting, tax, and legal	0		0	0	1.9
Loss on early extinguishment of debt	(0.3)		(2.6)	(10.7)	(7.4)
Interest expense and amortization of debt discounts and fees	36.8		42.5	118.5	130.5
Net income attributable to noncontrolling interests	$ 19.2		$ 16.4	$ 53.2	$ 53.7

Segment Reporting - Table 4 (De

Segment Reporting - Table 4 (Details) - USD ($) $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2017		Dec. 31, 2016
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets for reportable segments	$ 4,883.4	[1]	$ 4,681.9
Reclassification of noncurrent deferred income tax liabilities to net noncurrent deferred income tax assets	(70.4)		(71.4)
Total assets	4,883.4	[1]	4,681.9
Operating Segments [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets for reportable segments	4,953.8		4,753.3
Total assets	$ 4,953.8		$ 4,753.3
[1]	Our consolidated assets as of September 30, 2017 and December 31, 2016 include total assets of variable interest entities of $262.7 million and $262.3 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2017 and December 31, 2016 include total liabilities of the variable interest entities of $53.9 million and $50.3 million, respectively. See Note 3, Variable Interest Entities.

Segment Reporting - Table 5 (De

Segment Reporting - Table 5 (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 995.6	$ 926.8	$ 2,951.7	$ 2,757.3
Inpatient Rehabilitation Segment [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	794.8	751.7	2,377.3	2,253.5
Inpatient Rehabilitation Segment [Member] | Inpatient [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	768.6	724.1	2,297.7	2,164.6
Inpatient Rehabilitation Segment [Member] | Outpatient and other [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	26.2	27.6	79.6	88.9
Home Health and Hospice Segment [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	200.8	175.1	574.4	503.8
Home Health and Hospice Segment [Member] | Home health [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	181.2	162	519.4	470
Home Health and Hospice Segment [Member] | Hospice [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net operating revenues	$ 19.6	$ 13.1	$ 55	$ 33.8

Condensed Consolidating Finan65

Condensed Consolidating Financial Information - Narrative (Details)	Sep. 30, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Senior secured leverage ratio maximum	2
Consolidated coverage ratio minimum	2

Condensed Consolidating Finan66

Condensed Consolidating Financial Information - Income Statement Tables (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidating Statements of Operations
Net operating revenues	$ 995.6		$ 926.8	$ 2,951.7	$ 2,757.3
Less: Provision for doubtful accounts	(12.6)		(14.8)	(42.7)	(46.7)
Net operating revenues less provision for doubtful accounts	983		912	2,909	2,710.6
Operating expenses:
Salaries and benefits	542.1		497.4	1,600	1,469.6
Other operating expenses	137.6		126.3	397.2	367
Occupancy costs	18.6		17.6	54.8	53.5
Supplies	36.5		34.8	110.6	104.2
General and administrative expenses	39.7		30.3	128.6	96.6
Depreciation and amortization	46.2		43.5	137.2	128.8
Professional fees - accounting, tax, and legal	0		0	0	1.9
Total operating expenses	820.7		749.9	2,428.4	2,221.6
Loss on early extinguishment of debt	0.3	$ 10.4	2.6	10.7	7.4
Interest expense and amortization of debt discounts and fees	36.8		42.5	118.5	130.5
Other income	(1)		(0.8)	(2.9)	(2.1)
Equity in net income of nonconsolidated affiliates	(2.1)		(2.5)	(6.2)	(7.3)
Equity in net income of consolidated affiliates	0		0	0	0
Management fees	0		0	0	0
Income from continuing operations before income tax expense	128.3		120.3	360.5	360.5
Provision for income tax (benefit) expense	43.1		42.1	111.4	124.2
Income from continuing operations	85.2		78.2	249.1	236.3
Loss from discontinued operations, net of tax	(0.1)		(0.1)	(0.2)	(0.3)
Net income	85.1		78.1	248.9	236
Less: Net income attributable to noncontrolling interests	(19.2)		(16.4)	(53.2)	(53.7)
Net income attributable to HealthSouth	65.9		61.7	195.7	182.3
Comprehensive income	85.1		78	249.2	236.2
Comprehensive income attributable to HealthSouth	65.9		61.6	196	182.5
HealthSouth Corporation [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	5.3		4.9	15.9	14.9
Less: Provision for doubtful accounts	0		0	0	0
Net operating revenues less provision for doubtful accounts	5.3		4.9	15.9	14.9
Operating expenses:
Salaries and benefits	9.1		10.4	29.1	32.7
Other operating expenses	8		6.4	23.8	18.9
Occupancy costs	0.4		0.6	1.4	2.4
Supplies	0		0	0	0
General and administrative expenses	35.6		30.4	104.7	94.7
Depreciation and amortization	2		2.3	6.7	7.1
Professional fees - accounting, tax, and legal					1.9
Total operating expenses	55.1		50.1	165.7	157.7
Loss on early extinguishment of debt	0.3		2.6	10.7	7.4
Interest expense and amortization of debt discounts and fees	30.8		36.3	100.5	111.7
Other income	(5.7)		(5.1)	(16.5)	(14.6)
Equity in net income of nonconsolidated affiliates	0		0	0	0
Equity in net income of consolidated affiliates	(85)		(85.7)	(256.4)	(259.7)
Management fees	(35.8)		(33.9)	(107.8)	(101.9)
Income from continuing operations before income tax expense	45.6		40.6	119.7	114.3
Provision for income tax (benefit) expense	(20.4)		(21.2)	(76.2)	(68.3)
Income from continuing operations	66		61.8	195.9	182.6
Loss from discontinued operations, net of tax	(0.1)		(0.1)	(0.2)	(0.3)
Net income	65.9		61.7	195.7	182.3
Less: Net income attributable to noncontrolling interests	0		0	0	0
Net income attributable to HealthSouth	65.9		61.7	195.7	182.3
Comprehensive income	65.9		61.6	196	182.5
Comprehensive income attributable to HealthSouth	65.9		61.6	196	182.5
Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	555.2		541.8	1,693.9	1,621.2
Less: Provision for doubtful accounts	(7.7)		(10)	(27.3)	(32.1)
Net operating revenues less provision for doubtful accounts	547.5		531.8	1,666.6	1,589.1
Operating expenses:
Salaries and benefits	266.4		250.2	803.7	746.4
Other operating expenses	83.6		79.4	239.5	230.1
Occupancy costs	23.4		22.4	70	67.2
Supplies	22.4		22.4	69.4	67.1
General and administrative expenses	0		0	0	0
Depreciation and amortization	25.8		25.9	77.3	77.3
Professional fees - accounting, tax, and legal					0
Total operating expenses	421.6		400.3	1,259.9	1,188.1
Loss on early extinguishment of debt	0		0	0	0
Interest expense and amortization of debt discounts and fees	5.3		5.4	15.9	16.3
Other income	(0.1)		(0.1)	(0.2)	(0.2)
Equity in net income of nonconsolidated affiliates	(1.9)		(2.3)	(5.6)	(6.7)
Equity in net income of consolidated affiliates	(11.8)		(9.8)	(29.3)	(30.8)
Management fees	26.4		25.8	80.7	77
Income from continuing operations before income tax expense	108		112.5	345.2	345.4
Provision for income tax (benefit) expense	43.1		44.9	137.7	137.8
Income from continuing operations	64.9		67.6	207.5	207.6
Loss from discontinued operations, net of tax	0		0	0	0
Net income	64.9		67.6	207.5	207.6
Less: Net income attributable to noncontrolling interests	0		0	0	0
Net income attributable to HealthSouth	64.9		67.6	207.5	207.6
Comprehensive income	64.9		67.6	207.5	207.6
Comprehensive income attributable to HealthSouth	64.9		67.6	207.5	207.6
Nonguarantor Subsidiaries [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	466.5		409.8	1,336.2	1,209.2
Less: Provision for doubtful accounts	(4.9)		(4.8)	(15.4)	(14.6)
Net operating revenues less provision for doubtful accounts	461.6		405	1,320.8	1,194.6
Operating expenses:
Salaries and benefits	271.9		241.4	783	704.2
Other operating expenses	58.2		52.3	170.2	152.4
Occupancy costs	8.7		7.9	25.6	23.8
Supplies	14.1		12.4	41.2	37.1
General and administrative expenses	4.1		(0.1)	23.9	1.9
Depreciation and amortization	18.4		15.3	53.2	44.4
Professional fees - accounting, tax, and legal					0
Total operating expenses	375.4		329.2	1,097.1	963.8
Loss on early extinguishment of debt	0		0	0	0
Interest expense and amortization of debt discounts and fees	6.3		5.8	18.1	17.2
Other income	(0.8)		(0.6)	(2.2)	(2)
Equity in net income of nonconsolidated affiliates	(0.2)		(0.2)	(0.6)	(0.6)
Equity in net income of consolidated affiliates	0		0	0	0
Management fees	9.4		8.1	27.1	24.9
Income from continuing operations before income tax expense	71.5		62.7	181.3	191.3
Provision for income tax (benefit) expense	20.4		18.4	49.9	54.7
Income from continuing operations	51.1		44.3	131.4	136.6
Loss from discontinued operations, net of tax	0		0	0	0
Net income	51.1		44.3	131.4	136.6
Less: Net income attributable to noncontrolling interests	(19.2)		(16.4)	(53.2)	(53.7)
Net income attributable to HealthSouth	31.9		27.9	78.2	82.9
Comprehensive income	51.1		44.3	131.4	136.6
Comprehensive income attributable to HealthSouth	31.9		27.9	78.2	82.9
Consolidation, Eliminations [Member]
Condensed Consolidating Statements of Operations
Net operating revenues	(31.4)		(29.7)	(94.3)	(88)
Less: Provision for doubtful accounts	0		0	0	0
Net operating revenues less provision for doubtful accounts	(31.4)		(29.7)	(94.3)	(88)
Operating expenses:
Salaries and benefits	(5.3)		(4.6)	(15.8)	(13.7)
Other operating expenses	(12.2)		(11.8)	(36.3)	(34.4)
Occupancy costs	(13.9)		(13.3)	(42.2)	(39.9)
Supplies	0		0	0	0
General and administrative expenses	0		0	0	0
Depreciation and amortization	0		0	0	0
Professional fees - accounting, tax, and legal					0
Total operating expenses	(31.4)		(29.7)	(94.3)	(88)
Loss on early extinguishment of debt	0		0	0	0
Interest expense and amortization of debt discounts and fees	(5.6)		(5)	(16)	(14.7)
Other income	5.6		5	16	14.7
Equity in net income of nonconsolidated affiliates	0		0	0	0
Equity in net income of consolidated affiliates	96.8		95.5	285.7	290.5
Management fees	0		0	0	0
Income from continuing operations before income tax expense	(96.8)		(95.5)	(285.7)	(290.5)
Provision for income tax (benefit) expense	0		0	0	0
Income from continuing operations	(96.8)		(95.5)	(285.7)	(290.5)
Loss from discontinued operations, net of tax	0		0	0	0
Net income	(96.8)		(95.5)	(285.7)	(290.5)
Less: Net income attributable to noncontrolling interests	0		0	0	0
Net income attributable to HealthSouth	(96.8)		(95.5)	(285.7)	(290.5)
Comprehensive income	(96.8)		(95.5)	(285.7)	(290.5)
Comprehensive income attributable to HealthSouth	$ (96.8)		$ (95.5)	$ (285.7)	$ (290.5)

Condensed Consolidating Finan67

Condensed Consolidating Financial Information - Balance Sheet Tables (Details) - USD ($) $ in Millions	Sep. 30, 2017		Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 67.6		$ 40.5	$ 76.4	$ 61.6
Accounts receivable, net	441.6		443.8
Other current assets	178.2		170.2
Total current assets	687.4		654.5
Property and equipment, net	1,482.3		1,391.8
Goodwill	1,971.7		1,927.2
Intangible assets, net	405.1		411.3
Deferred income tax assets	91.6		75.8
Other long-term assets	245.3		221.3
Intercompany notes receivable	0		0
Intercompany receivable and investments in consolidated affiliates	0		0
Total assets	4,883.4	[1]	4,681.9
Current liabilities:
Current portion of long-term debt	31.1		37.1
Accounts payable	81.8		68.3
Accrued expenses and other current liabilities	398.3		370.2
Total current liabilities	511.2		475.6
Long-term debt, net of current portion	2,591.3		2,979.3
Intercompany notes payable	0		0
Other long-term liabilities	186.4		160
Intercompany payable	0		0
Total Liabilities	3,288.9		3,614.9
Commitments and contingencies
Redeemable noncontrolling interests	221.3		138.3
Shareholders' equity:
HealthSouth shareholders’ equity	1,136.4		735.9
Noncontrolling interests	236.8		192.8
Total shareholders’ equity	1,373.2		928.7	913.8	779.3
Total liabilities and shareholders' equity	4,883.4	[1]	4,681.9
HealthSouth Corporation [Member]
Current assets:
Cash and cash equivalents	46.4		20.6	56.1	41.2
Accounts receivable, net	0		0
Other current assets	66		49.9
Total current assets	112.4		70.5
Property and equipment, net	87.7		41.6
Goodwill	0		0
Intangible assets, net	11.6		12
Deferred income tax assets	106.5		90.9
Other long-term assets	50.9		49
Intercompany notes receivable	503.4		528.8
Intercompany receivable and investments in consolidated affiliates	2,821.6		2,855.5
Total assets	3,694.1		3,648.3
Current liabilities:
Current portion of long-term debt	32.7		40
Accounts payable	11.2		7
Accrued expenses and other current liabilities	180.7		150.7
Total current liabilities	224.6		197.7
Long-term debt, net of current portion	2,301.7		2,679.2
Intercompany notes payable	0		0
Other long-term liabilities	31.4		35.5
Intercompany payable	0		0
Total Liabilities	2,557.7		2,912.4
Commitments and contingencies
Redeemable noncontrolling interests	0		0
Shareholders' equity:
HealthSouth shareholders’ equity	1,136.4		735.9
Noncontrolling interests	0		0
Total shareholders’ equity	1,136.4		735.9
Total liabilities and shareholders' equity	3,694.1		3,648.3
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	3.3		1.6	0.3	1.2
Accounts receivable, net	266.4		273.3
Other current assets	22.1		24
Total current assets	291.8		298.9
Property and equipment, net	977.3		979.7
Goodwill	854.6		858.4
Intangible assets, net	107.5		115.5
Deferred income tax assets	57.7		57.6
Other long-term assets	107.3		95.1
Intercompany notes receivable	0		0
Intercompany receivable and investments in consolidated affiliates	221.1		107.7
Total assets	2,617.3		2,512.9
Current liabilities:
Current portion of long-term debt	7.2		6.4
Accounts payable	46.2		37.2
Accrued expenses and other current liabilities	84.9		81.7
Total current liabilities	138.3		125.3
Long-term debt, net of current portion	244.2		248.9
Intercompany notes payable	0		0
Other long-term liabilities	17		15.2
Intercompany payable	0		0
Total Liabilities	399.5		389.4
Commitments and contingencies
Redeemable noncontrolling interests	0		0
Shareholders' equity:
HealthSouth shareholders’ equity	2,217.8		2,123.5
Noncontrolling interests	0		0
Total shareholders’ equity	2,217.8		2,123.5
Total liabilities and shareholders' equity	2,617.3		2,512.9
Nonguarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	17.9		18.3	20	19.2
Accounts receivable, net	175.2		170.5
Other current assets	130.6		114.9
Total current assets	323.7		303.7
Property and equipment, net	417.3		370.5
Goodwill	1,117.1		1,068.8
Intangible assets, net	286		283.8
Deferred income tax assets	0		0
Other long-term assets	87.1		77.2
Intercompany notes receivable	0		0
Intercompany receivable and investments in consolidated affiliates	0		0
Total assets	2,231.2		2,104
Current liabilities:
Current portion of long-term debt	8.7		8.2
Accounts payable	24.4		24.1
Accrued expenses and other current liabilities	155.7		138.9
Total current liabilities	188.8		171.2
Long-term debt, net of current portion	45.4		51.2
Intercompany notes payable	503.4		528.8
Other long-term liabilities	210.4		181.6
Intercompany payable	135.8		167.6
Total Liabilities	1,083.8		1,100.4
Commitments and contingencies
Redeemable noncontrolling interests	221.3		138.3
Shareholders' equity:
HealthSouth shareholders’ equity	689.3		672.5
Noncontrolling interests	236.8		192.8
Total shareholders’ equity	926.1		865.3
Total liabilities and shareholders' equity	2,231.2		2,104
Consolidation, Eliminations [Member]
Current assets:
Cash and cash equivalents	0		0	$ 0	$ 0
Accounts receivable, net	0		0
Other current assets	(40.5)		(18.6)
Total current assets	(40.5)		(18.6)
Property and equipment, net	0		0
Goodwill	0		0
Intangible assets, net	0		0
Deferred income tax assets	(72.6)		(72.7)
Other long-term assets	0		0
Intercompany notes receivable	(503.4)		(528.8)
Intercompany receivable and investments in consolidated affiliates	(3,042.7)		(2,963.2)
Total assets	(3,659.2)		(3,583.3)
Current liabilities:
Current portion of long-term debt	(17.5)		(17.5)
Accounts payable	0		0
Accrued expenses and other current liabilities	(23)		(1.1)
Total current liabilities	(40.5)		(18.6)
Long-term debt, net of current portion	0		0
Intercompany notes payable	(503.4)		(528.8)
Other long-term liabilities	(72.4)		(72.3)
Intercompany payable	(135.8)		(167.6)
Total Liabilities	(752.1)		(787.3)
Commitments and contingencies
Redeemable noncontrolling interests	0		0
Shareholders' equity:
HealthSouth shareholders’ equity	(2,907.1)		(2,796)
Noncontrolling interests	0		0
Total shareholders’ equity	(2,907.1)		(2,796)
Total liabilities and shareholders' equity	$ (3,659.2)		$ (3,583.3)
[1]	Our consolidated assets as of September 30, 2017 and December 31, 2016 include total assets of variable interest entities of $262.7 million and $262.3 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2017 and December 31, 2016 include total liabilities of the variable interest entities of $53.9 million and $50.3 million, respectively. See Note 3, Variable Interest Entities.

Condensed Consolidating Finan68

Condensed Consolidating Financial Information - Cash Flow Statement Tables (Details) - USD ($) $ in Millions	1 Months Ended		9 Months Ended
	May 31, 2017	Jan. 17, 2017	Sep. 30, 2017	Sep. 30, 2016
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities			$ 505.8	$ 499.4
Cash flows from investing activities:
Purchases of property and equipment			(155.7)	(113.9)
Additions to capitalized software costs			(14.6)	(17.5)
Acquisitions of businesses, net of cash acquired			(36.6)	(19.6)
Net change in restricted cash			(9.9)	(7.1)
Origination of Notes Receivable from Related Parties				0
Proceeds from repayment of intercompany notes receivable			0	0
Other, net			7.6	1.8
Net cash used in investing activities			(209.2)	(156.3)
Cash flows from financing activities:
Principal payments on debt, including pre-payments			(125.4)	(195.2)
Principal borrowings on intercompany note receivable				0
Principal payments on intercompany note payable			0	0
Borrowings on revolving credit facility			241.3	260
Payments on revolving credit facility			(255.3)	(240)
Repurchases of common stock, including fees and expenses			(38.1)	(24.1)
Dividends paid on common stock			(67)	(62.4)
Proceeds from exercising stock warrants		$ 27	26.6	0
Distributions paid to noncontrolling interests of consolidated affiliates			(38.3)	(49.5)
Taxes paid on behalf of employees for shares withheld			(19.8)	(9.9)
Other, net			6.5	(7.2)
Change in intercompany advances			0	0
Net cash used in financing activities			(269.5)	(328.3)
Increase (decrease) in cash and cash equivalents			27.1	14.8
Cash and cash equivalents at beginning of period		40.5	40.5	61.6
Cash and cash equivalents at end of period			67.6	76.4
Supplemental schedule of noncash investing and financing activity
Conversion of convertible debt	$ 319.4		319.4	0
HealthSouth Corporation [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities			47	88.6
Cash flows from investing activities:
Purchases of property and equipment			(23.5)	(9.2)
Additions to capitalized software costs			(12.1)	(15.9)
Acquisitions of businesses, net of cash acquired			(10.9)	0
Net change in restricted cash			0	0
Origination of Notes Receivable from Related Parties				(11.5)
Proceeds from repayment of intercompany notes receivable			33	22
Other, net			(2.7)	(3.3)
Net cash used in investing activities			(16.2)	(17.9)
Cash flows from financing activities:
Principal payments on debt, including pre-payments			(123.1)	(192.9)
Principal borrowings on intercompany note receivable				0
Principal payments on intercompany note payable			0	0
Borrowings on revolving credit facility			241.3	260
Payments on revolving credit facility			(255.3)	(240)
Repurchases of common stock, including fees and expenses			(38.1)	(24.1)
Dividends paid on common stock			(67)	(62.4)
Proceeds from exercising stock warrants			26.6
Distributions paid to noncontrolling interests of consolidated affiliates			0	0
Taxes paid on behalf of employees for shares withheld			(19.5)	(9.9)
Other, net			(1.5)	3.3
Change in intercompany advances			231.6	210.2
Net cash used in financing activities			(5)	(55.8)
Increase (decrease) in cash and cash equivalents			25.8	14.9
Cash and cash equivalents at beginning of period		20.6	20.6	41.2
Cash and cash equivalents at end of period			46.4	56.1
Supplemental schedule of noncash investing and financing activity
Conversion of convertible debt			319.4
Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities			261.5	260.2
Cash flows from investing activities:
Purchases of property and equipment			(67.7)	(54.2)
Additions to capitalized software costs			(0.2)	(0.1)
Acquisitions of businesses, net of cash acquired			0	0
Net change in restricted cash			0	0
Proceeds from repayment of intercompany notes receivable			0	0
Other, net			11.7	0.5
Net cash used in investing activities			(56.2)	(53.8)
Cash flows from financing activities:
Principal payments on debt, including pre-payments			0	(1.3)
Principal borrowings on intercompany note receivable				0
Principal payments on intercompany note payable			0	0
Borrowings on revolving credit facility			0	0
Payments on revolving credit facility			0	0
Repurchases of common stock, including fees and expenses			0	0
Dividends paid on common stock			0	0
Proceeds from exercising stock warrants			0
Distributions paid to noncontrolling interests of consolidated affiliates			0	0
Taxes paid on behalf of employees for shares withheld			0	0
Other, net			(5)	(4.4)
Change in intercompany advances			(198.6)	(201.6)
Net cash used in financing activities			(203.6)	(207.3)
Increase (decrease) in cash and cash equivalents			1.7	(0.9)
Cash and cash equivalents at beginning of period		1.6	1.6	1.2
Cash and cash equivalents at end of period			3.3	0.3
Supplemental schedule of noncash investing and financing activity
Conversion of convertible debt			0
Nonguarantor Subsidiaries [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities			197.3	150.6
Cash flows from investing activities:
Purchases of property and equipment			(64.5)	(50.5)
Additions to capitalized software costs			(2.3)	(1.5)
Acquisitions of businesses, net of cash acquired			(25.7)	(19.6)
Net change in restricted cash			(9.9)	(7.1)
Proceeds from repayment of intercompany notes receivable			0	0
Other, net			(1.4)	4.6
Net cash used in investing activities			(103.8)	(74.1)
Cash flows from financing activities:
Principal payments on debt, including pre-payments			(2.3)	(1)
Principal borrowings on intercompany note receivable				11.5
Principal payments on intercompany note payable			(33)	(22)
Borrowings on revolving credit facility			0	0
Payments on revolving credit facility			0	0
Repurchases of common stock, including fees and expenses			0	0
Dividends paid on common stock			0	0
Proceeds from exercising stock warrants			0
Distributions paid to noncontrolling interests of consolidated affiliates			(38.3)	(49.5)
Taxes paid on behalf of employees for shares withheld			(0.3)	0
Other, net			13	(6.1)
Change in intercompany advances			(33)	(8.6)
Net cash used in financing activities			(93.9)	(75.7)
Increase (decrease) in cash and cash equivalents			(0.4)	0.8
Cash and cash equivalents at beginning of period		18.3	18.3	19.2
Cash and cash equivalents at end of period			17.9	20
Supplemental schedule of noncash investing and financing activity
Conversion of convertible debt			0
Consolidation, Eliminations [Member]
Condensed Consolidating Statements of Cash Flows
Net cash provided by operating activities			0	0
Cash flows from investing activities:
Purchases of property and equipment			0	0
Additions to capitalized software costs			0	0
Acquisitions of businesses, net of cash acquired			0	0
Net change in restricted cash			0	0
Origination of Notes Receivable from Related Parties				11.5
Proceeds from repayment of intercompany notes receivable			(33)	(22)
Other, net			0	0
Net cash used in investing activities			(33)	(10.5)
Cash flows from financing activities:
Principal payments on debt, including pre-payments			0	0
Principal borrowings on intercompany note receivable				(11.5)
Principal payments on intercompany note payable			33	22
Borrowings on revolving credit facility			0	0
Payments on revolving credit facility			0	0
Repurchases of common stock, including fees and expenses			0	0
Dividends paid on common stock			0	0
Proceeds from exercising stock warrants			0
Distributions paid to noncontrolling interests of consolidated affiliates			0	0
Taxes paid on behalf of employees for shares withheld			0	0
Other, net			0	0
Change in intercompany advances			0	0
Net cash used in financing activities			33	10.5
Increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents at beginning of period		$ 0	0	0
Cash and cash equivalents at end of period			0	$ 0
Supplemental schedule of noncash investing and financing activity
Conversion of convertible debt			$ 0